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resumo 
 
 
Estudos recentes indicam que as modificações de tRNAs e as enzimas 
modificadoras de tRNAs desempenham papéis importantes em doenças 
Humanas complexas como são exemplos: cancro, doenças neurológicas e 
mitocondriais.  
Conjecturamos que a desregulação na expressão das enzimas 
modificadoras de tRNAs afecta o nível de modificações dos tRNAs e, 
consequentemente, as suas funções e eficiência de tradução dos codões 
correspondentes aos tRNAs que afectam. Devido à degeneração do código 
genético, a maior parte dos aminoácidos são codificados por dois a seis 
codões sinónimos. Esta degeneração e o uso tendencioso de codões 
sinónimos causam alterações que podem ir desde problemas de enovelamento 
proteico a um aumento de eficiência de tradução de um grupo de genes 
específico. 
Neste trabalho, focámo-nos no cancro e fizemos um estudo de meta-
análise para comparar perfis de expressão génica de microarrays, onde foram 
encontradas enzimas modificadoras de tRNA desreguladas e analisar o codon 
usage dos diferentes tipos de cancro nestes dados, reportados em estudos 
anteriores.  
Encontrámos um total de 36 diferentes enzimas modificadoras de tRNAs 
que se encontram desreguladas na maior parte das datasets de cancro 
analisadas. A análise de codon usage revelou uma preferência, por parte dos 
genes sobre-expressos, por codões acabados em AU e uma preferência por 
codões acabados em GC, em genes sub-expressos. Uma subsequente análise 
de PCA biplot veio mostrar esta mesma tendência. Analisámos também o 
codon usage de datasets onde a enzima modificadora de tRNA CTU2 se 
encontrava desregulada uma vez que esta enzima afecta a posição “wobble” 
(posição 34) de tRNAs específicos. 
Os nossos dados apontam para um padrão de codon usage distinto entre 
genes sobre-expressos e sub-expressos em cancro, que pode ser causado 
pela desregulação de enzimas modificadores de tRNA específicas. Esta 
tendência de codon usage pode aumentar a transcrição e eficiência de 
tradução de alguns genes que, de outra forma, numa situação normal, seriam 
traduzidos de forma menos eficiente. 
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abstract 
 
Recent evidences indicate that tRNA modifications and tRNA modifying 
enzymes may play important roles in complex human diseases such as cancer, 
neurological disorders and mitochondrial-linked diseases. 
We postulate that expression deregulation of tRNA modifying enzymes 
affects the level of tRNA modifications and, consequently, their function and the 
translation efficiency of their tRNA corresponding codons. Due to the 
degeneracy of the genetic code, most amino acids are encoded by two to six 
synonymous codons. This degeneracy and the biased usage of synonymous 
codons cause alterations that can span from protein folding to enhanced 
translation efficiency of a select gene group. 
 In this work, we focused on cancer and performed a meta-analysis study to 
compare microarray gene expression profiles, reported by previous studies and 
evaluate the codon usage of different types of cancer where tRNA modifying 
enzymes were found de-regulated. 
A total of 36 different tRNA modifying enzymes were found de-regulated in 
most cancer datasets analyzed. The codon usage analysis revealed a 
preference for codons ending in AU for the up-regulated genes, while the 
down-regulated genes show a preference for GC ending codons. Furthermore, 
a PCA biplot analysis showed this same tendency. We also analyzed the codon 
usage of the datasets where the CTU2 tRNA modifying enzyme was found 
deregulated as this enzyme affects the wobble position (position 34) of specific 
tRNAs. 
Our data points to a distinct codon usage pattern between up and down-
regulated genes in cancer, which might be caused by the deregulation of 
specific tRNA modifying enzymes. This codon usage bias may augment the 
transcription and translation efficiency of some genes that otherwise, in a 
normal situation, would be translated less efficiently. 
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1. Introduction 
Cells are the fundamental units of life and their genetic information is stored in 
the genome in the form of double stranded molecules of deoxyribonucleic acid 
(DNA) (Alberts et al., 2008). This information is used to produce proteins - long 
unbranched polymer chains, formed by stringing together monomeric building 
blocks, named amino acids - that are crucial to construct and maintain life (Alberts 
et al., 2008; Brown, 2007). In order to do so, the information carried in DNA is 
transcribed into a molecule of messenger ribonucleic acid (mRNA), through a 
process designated as transcription. This molecule is then translated into a protein 
by a process called translation. In this process, the information in the mRNA is 
interpreted by a second type of RNA called transfer RNA (tRNA) with the aid of a 
third type of RNA, ribosomal RNA (rRNA), and its associated proteins (Lodish, 
2008) composing the structure known as the ribosome. 
 
1.1. Central dogma 
Crick postulated that the genetic information follows a sequential transition 
from DNA to mRNA and from mRNA to protein and this concept constitutes the 
central dogma of molecular biology (Crick, 1970). This dogma also states that 
such information cannot be transferred back from protein to nucleic acid (Figure 1) 
(Crick, 1970). 
 
Figure 1 – Central dogma of molecular biology. Solid arrows show general transfers and 
dotted arrows show special transfers (Crick, 1970). 
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1.2. Gene translation 
Translation is the process by which the nucleotide sequence of an mRNA is 
translated to amino acids, which bond in a polypeptide chain (Lodish, 2008). In 
eukaryotic cells, the translation of an mRNA molecule into protein takes place in 
the cytosol on a large ribonucleoprotein assembly called ribosome (Alberts et al., 
2008). The ribosome is called a ribonucleoprotein because it is composed of rRNA 
and proteins. Each ribosome comprises two subunits. In Eukaryotes, these are the 
40S small subunit and 60S large subunit (Brown, 2007). The ribosomes coordinate 
protein synthesis by placing mRNA, aminoacyl-tRNAs and associated protein 
factors in their correct position relative to one another (Brown, 2007). 
The translation process can be divided into three main stages: initiation, 
elongation and termination (Allison, 2007), which are described below. Each stage 
of protein synthesis involves multiple accessory factors and energy from GTP 
hydrolysis.  
Initiation is the most complex and the most tightly controlled step in protein 
synthesis, involving the assembly of the ternary complex eIF2-GTP-Met-tRNAMet-i, 
comprised of eukaryotic initiation factor 2 (eIF2), GTP and the amino acid-charged 
tRNA (met-tRNA; bound at the ribosome P site) at the initiation codon (Allison, 
2007) (Figure 2). 
 
Figure 2 – Formation of the ternary complex (adapted from Jackson et al., 2010). 
 
This complex binds to the 40S ribosomal subunit, in association with initiation 
factors eIF1, eIF1A and eIF3 (Brown, 2007) to form the 43S complex. Two 
features of the eukaryotic mRNA become important at this point: the 5’ cap and 
the 3’-poly(A) tail (Allison, 2007). The eIF4F complex (eIF4A, eIF4E and eIF4G) 
(Brown, 2007) assembles on the 5’ cap of the mRNA and unwinds the structures 
found in the 5’ untranslated region (UTR) using the ATP dependent action of the 
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eIF4A subunit (Kapp and Lorsch, 2004). The eIF4F along eIF3 and the poly(A) 
binding protein (PAB) bound to the 3’-poly(A) tail, loads the mRNA onto the 43S 
complex (Figure 3) (Kapp and Lorsch, 2004). Once the mRNA is loaded, the 43S 
complex begins scanning down the message in the 5’ to 3’ direction, searching the 
initiation codon (Allison, 2007). 
When the 43S complex encounters the initiation codon, usually embedded in a 
favorable short consensus sequence referred as Kozak sequence, codon- 
anticodon base pairing takes place between the initiation codon and the initiator 
tRNA in the ternary complex and the scanning stops (Brown, 2007; Kapp and 
Lorsch, 2004; Lodish, 2008). Recognition of the start codon leads to the arrest of 
the ribosomal complex forming a stable 48S complex (Allison, 2007). It also leads 
to the hydrolysis of the GTP associated with eIF2, (Kapp and Lorsch, 2004; 
Lodish, 2008). After GTP hydrolysis eIF2·GDP releases the met-tRNAi into the P 
site, dissociating from the complex, along with eIF1, eIF3 and eIF5 (Jackson et al., 
2010; Kapp and Lorsch, 2004). Then, eIF5B·GTP binds to the complex and 
facilitates the joining of the 60S ribosomal subunit (Kapp and Lorsch, 2004). This 
event triggers GTP hydrolysis by eIF5B and it dissociates from the complex along 
with eIF1A, forming the 80S complex (Figure 3) (Allison, 2007; Jackson et al., 
2010; Kapp and Lorsch, 2004). 
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Figure 3 – Overview of the translation initiation process that is divided into eight stages (2-
9) (Jackson et al., 2010). 
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The elongation step occurs rapidly. During this step, the aminoacyl-tRNAs, 
carried out in a form of ternary complex with GTP and elongation factor eEF1A, 
(eEF1A·GTP·aa-tRNA) (Figure 4(1)) enter the acceptor (A) site of the ribosome, 
where decoding takes place (Kapp and Lorsch, 2004). Only the cognate tRNA 
binds to the A site of the ribosome and this selection is carried out by several 
steps involving conformational changes in the 40S subunit and GTP hydrolysis by 
eEF1A, resulting in a tight binding of the aminoacyl-tRNA in the A site and release 
of the resulting eEF1A·GDP complex  (Kapp and Lorsch, 2004; Lodish, 2008). If 
they are the correct (cognate) tRNAs, i.e., if the aminoacyl-tRNAs are 
complementary to codons in the mRNA, the ribosome catalyzes the formation of a 
peptide bond between the incoming amino acid (bound at the A site) and the 
initiating peptidyl tRNA (at the P site) (Figure 4(2)) (Kapp and Lorsch, 2004; 
Lodish, 2008). The complex is then translocated along the mRNA in a step 
promoted by hydrolysis of the GTP in eEF2·GTP, resulting in deacylated tRNA 
movement to the ribosome exit (E) site and the peptidyl tRNA to the P site (Figure 
4(3)), leaving the A site free to receive another eEF1A·GTP·aa-tRNA ternary 
complex (Lodish, 2008). After the hydrolysis the eEF1A·GDP complex formed is 
dissociated and this complex must be recycled to its GTP-bound form so that it 
may participate in successive rounds of polypeptide elongation, accomplished by a 
multifactor complex eEF1B (eEF1Bα and eEF1Bβ) (Kapp and Lorsch, 2004). 
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Figure 4 – The eukaryotic translation elongation cycle that is divided into three stages 
(1-3) (Schneider-Poetsch et al., 2010). 
 
The termination of translation takes place when a stop codon is encountered 
by the ribosome in the A site, which leads to the hydrolysis of the ester bond 
linking the polypeptide chain to the P site and release of the completed 
polypeptide (Kapp and Lorsch, 2004). The recognition of all three stop codons, 
namely UAA, UAG and UGA is due to the release factor eRF1, which binds in the 
A site and stimulates the release factor eRF3, a GTPase that triggers the release 
of eRF1 from the ribosome following peptidyl-tRNA hydrolysis (Figure 5) (Kapp 
and Lorsch, 2004). 
The final step in termination is the process of recycling of the ribosomal 
subunits so that they can be used in another round of initiation. This process is not 
well understood in eukaryotes (Allison, 2007). However, the closed-loop model of 
eukaryotic mRNAs has suggested the possibility that termination and recycling 
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may not release the 40S subunit. Instead, it may be shuttled across or over the 
poly(A) tail back to the 5' end of the mRNA via the 5’ and 3’ end associated 
factors. In this model, the closed loop serves to facilitate reinitiation of translation 
rather than the first initiation event (Kapp and Lorsch, 2004). 
 
Figure 5 – Translation termination (adapted from Graille and Seraphin, 2012). 
 
1.3. The genetic code 
The genetic code used by the cells is a triplet code, composed by four different 
nucleotides in DNA: adenine (A), cytosine (C), guanine (G) and thymine (T). In 
RNA uracil (U) is used instead of thymine. Every three-nucleotide sequence 
corresponds to a codon that is “read” from a specified starting point in the mRNA. 
Of the 64 possible codons (Figure 6), 61 specify individual amino acids and are 
recognized by tRNAs for the incorporation of the 20 common aminoacids (Allison, 
2007; Lodish, 2008). The other three are stop codons that signal termination of 
protein synthesis, or code for selenocysteine and pyrrolysine, the 21st and 22nd 
amino acids, respectively (Allison, 2007; Lodish, 2008).  
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Figure 6 – Historical presentation of the genetic code, each 
“codon box” is composed of four three-letter codes, 64 in all (Agris et al., 2007). 
 
The genetic code is said to be degenerated because most amino acids are 
encoded by two to six synonymous codons (Chen et al., 2014). This means that 
some tRNAs recognize more than one codon. Francis Crick proposed a 
mechanism to explain how tRNAs can read more than one codon - the Wobble 
Hypothesis (Crick, 1966). Briefly, this hypothesis states that the third position of 
the codon and the first position of the anticodon present a looser connection than 
the other pair, which may lead to unusual base combinations (Lehninger et al., 
2005). 
However, even though synonymous codons encode the same amino acids, it 
has been shown for a wide variety of organisms that different synonymous codons 
are used with different frequencies. This unique feature has been termed codon 
bias (Hershberg and Petrov, 2008).  
Because there is a difference in codon usage, homologous sequences of the 
individual members of protein families may be coded in different ways within the 
same genome. Likewise, classes of genes within the same genome that are 
physiologically regulated to different expression levels may have class-specific 
codon preferences (Kurland, 1991). Codon usage preferences are also closely 
correlated to abundance of the correspondent tRNA (Gustafsson et al., 2004; 
Ikemura, 1985; Novoa et al., 2012; Percudani et al., 1997). 
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1.4.   Codon usage bias 
The codon usage bias varies significantly between organisms. Thus, the most 
frequent or most rare codon in a gene varies both between and within species 
depending on the gene (Novoa et al., 2012). 
There are two main lines of thought about codon usage bias: the selectionist 
and the mutational explanations (Hershberg and Petrov, 2008). According to the 
selectionist explanation, codon bias contributes to the efficiency and accuracy of 
amino acid sequence and this bias is maintained by selection (Bulmer, 1991). By 
contrast, the mutational theory suggests that codon bias exists because of non-
randomness in the mutational patterns, whereby some codons would be more 
mutable and, therefore, would have lower equilibrium frequencies (Akashi, 1994). 
According to this latter theory, genomic G+C composition is thought to be a major 
factor affecting codon usage variation (Chen et al., 2004). 
A clear association exists between the expression level of a gene and its codon 
composition. This observation holds for organisms ranging from bacteria to 
mammals (Novoa and Ribas de Pouplana, 2012).  For example, codon usage bias 
has been linked to the control of cell cycle development (Chartier et al., 2012) and 
stress-mediated specific responses (Frenkel-Morgenstern et al., 2012). Specific 
tRNAs and, consequently, certain codon compositions are crucial components in 
the activation of some genetic programs (Begley et al., 2007), suggesting a novel 
layer of genomic regulation that is only now starting to be explored (Novoa and 
Ribas de Pouplana, 2012) 
 
1.5. Transfer RNAs  
Transfer RNAs (tRNAs) are a family of non-coding RNAs of approximately 70-
100 nucleotides in length that fold into a “clover leaf” secondary structure and a L-
shaped tertiary structure (Figure 7) (Kim et al., 1973; Torres et al., 2014). 
The secondary structure consists of a series of double-stranded and single-
stranded stems stabilized by Watson-Crick base pairing (Sprinzl et al., 1998). The 
overall structure is composed of four stems: an aminoacyl stem, D-arm, T-arm and 
anticodon arm (Figure 7). In all tRNAs, the 3’ end of the unlooped amino acid 
acceptor stem has the sequence CCA, which in most cases is added after 
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synthesis and processing of the tRNA are complete (Lodish, 2008). Some of the A, 
C, G, and U residues are modified in most tRNAs. Dihydrouridine (D) is nearly 
always present in the D loop. Likewise, ribothymidine (T) and pseudouridine () are 
almost always present in the T loop. These stems owe their name to the 
corresponding conserved modifications found in them (Björk et al., 1999). 
 
 
Figure 7 – Structure of tRNA: (A) clover leaf structure of tRNA; the numbers show the 
positions of the nucleotides and (B) L-shaped tRNA structure: transfer RNA forms an L-
shaped structure, in which the D- and T-arms interact by tertiary base pairs (Hori, 2014). 
 
These molecules are present in all living organisms and act as adaptors that 
link amino acids to codons in messenger RNAs (mRNA) (Novoa et al., 2012). 
Therefore, tRNAs are central to the decoding process and interact with most 
components of the translation apparatus. 
Despite their recognized importance in the decoding process of translation, 
tRNAs play important roles in other cellular processes non-related to translation. 
An example of these processes is the use of aminoacylated tRNAs as amino 
acid donors for N-terminal conjugation of amino acids to proteins, targeting the 
recipient proteins for degradation (Mogk et al., 2007; Varshavsky, 1997).  
Another one concerns the role of uncharged tRNAs in signal transduction 
pathways responding to nutrient deprivation (Dever and Hinnebusch, 2005). 
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tRNAs have also been implicated recently in regulation of apoptosis in mammalian 
cells (Mei et al., 2010). These studies showed that tRNAs bind cytochrome c, 
thereby preventing the interaction of cytochrome c with the caspase activator 
Apaf-1 and preventing its activation. Also, recent reports have emerged 
suggesting that tRNA cleavage products inhibit translation. These cleavage 
products result from multiple tRNA degradation pathways and mechanisms 
(Phizicky and Hopper, 2010). 
Conversely, inappropriate regulation of tRNA (tRNAi
Met) transcription can 
promote cell proliferation and immortalization as well as tumors in mice (Marshall 
et al., 2008). These results provide new ways to think about how tRNA cellular 
levels influence cell growth and oncogenesis.  
Recent studies have also implicated tRNAs as elements of control of their 
cognate aaRS expression (Ryckelynck et al., 2005). 
tRNA genes are highly transcribed leading to the production in yeast of ∼3 
million tRNAs per generation (Waldron and Lacroute, 1975), compared with about 
60,000 mRNAs (Ares et al., 1999). 
After maturation, tRNAs are charged with their cognate amino acid at the 3’-
end, in a reaction called aminoacylation and catalyzed by aminoacyl-tRNA 
synthetases (Attardi, 1967) and, through their anticodon loop nucleobases located 
at positions 34, 35 and 36 pair specifically with codons in mRNA (Figure 8). 
 
Figure 8 – Codon-anticodon base pairing (adapted from El Yacoubi et al., 2012). 
 
Therefore, the tRNA decodes the genetic message with the help of the 
aminoacyl-tRNA synthetases (Schimmel and Söll, 1979; Swanson et al., 1988)  
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Position 34 can wobble and pair with different nucleotides at the third position 
of the mRNA codon via non-Watson-Crick interactions (A/U, U/A, G/C, C/G) 
(Crick, 1966; Ladner et al., 1975). Wobbling at position 34 of tRNA is important 
because it allows some tRNAs to decode different sets of codons coding for the 
same amino acid and some codons to be recognized by more than one anticodon 
sequence (Agris et al., 2007). 
Because tRNAs decipher the genetic material, proper decoding by these 
molecules is crucial for cell survival (El Yacoubi et al., 2012). Whereas 
polypeptides use a chemical diverse set of building blocks (the 20 proteogenic 
aminoacids), tRNA molecules are limited to four ribonucleotides incorporated 
during transcription. However, the chemical diversity of tRNAs are greatly 
augmented by the addition of posttranscriptional modifications, one of the multiple 
steps in tRNA maturation (Johansson and Byström, 2002).  
 
1.6. tRNA modifications  
Modified tRNAs are found universally in all living organisms, some conserved 
across all the life domains (Björk, 1986). All types of cellular RNAs contain 
modified nucleotides, but the largest number and greatest variety are found in 
tRNAs (McCloskey and Crain, 1998). The modified nucleotides are derivatives of 
the four major nucleotides and these modifications are catalyzed by tRNA 
modifying enzymes (Björk and Hagervall, 2014). Some modifications are constant 
features of all tRNA molecules, while others are specific to certain tRNAs or 
groups of tRNAs (Lewin et al., 2011). Modifications consist of simple chemical 
alterations of nucleosides (e.g. methylation of base or ribose, base isomerisation, 
reduction, thiolation or deamination) or more complex hypermodifications. The 
type of chemical alteration of a nucleoside as well as the pattern of tRNA 
modification depends on the origin of the tRNA molecule (Roovers et al., 2004). 
The tRNA modifying enzymes vary greatly in specificity. In some cases, a 
single enzyme acts to make a specific modification at a unique position, while in 
other cases an enzyme may modify bases at several different positions. 
Additionally, some enzymes are able to undertake the reaction with individual 
tRNAs, while others have a range of substrate molecules. It is probable that this 
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class of enzymes can recognize structural features surrounding the site of 
modification (Lewin et al., 2011). Cells apply a great amount of resources to the 
modification of tRNA. In fact, considerably more genetic information is allocated to 
tRNA modifications than to tRNA genes (Bjork, 1995). Furthermore, it is estimated 
that 1% to 10% of the genes in a given genome encode enzymes involved in tRNA 
modification (El Yacoubi et al., 2012).  
 
1.6.1. Types of tRNA modifications 
Currently, there are over 100 post-translation modifications that have been 
identified in tRNAs (Liu and Pan, 2015)  Among the vast amount of tRNA 
modifications there are deaminations, isomerizations, glycosylations, thiolation, 
transglycosylations and methylations (Jackman and Alfonzo, 2013). The core 
group of modified nucleotides is generally characterized by relatively simple 
chemical structures, such as: the addition of one (or two) methyl groups to various 
positions of the nucleotide bases and or ribose sugars (methylation), replacement 
of oxygen with sulfur (isomerization) or reduction of the uridine base to 
pseudouridine or dihydrouridine (Jackman and Alfonzo, 2013). One of the most 
common modification is methylation and they are spread all over the tRNA 
molecule (Müller et al., 2015). There are other modifications that are more specific. 
Many of these are currently well cataloged at the RNA Modification Database 
(http://mods.rna.albany.edu/mods/).  
 
1.6.2. Functions 
Chemical posttranscriptional modifications are crucial for tRNA structure, 
function and stability. In general, hypomodified tRNAs are targeted for 
degradation, so, a primary role of tRNA modifications is to prevent tRNAs from 
entering specific degradation pathways (Torres et al., 2014). From a functional 
point of view, specific modifications in the anticodon loop are generally used to 
tune decoding capacity and to control decoding accuracy, whereas modifications 
outside the anticodon loop are generally used to maintain tRNA stability or to 
modulate tRNA folding (Liu and Pan, 2015). Nucleotide modifications ensure that 
the decoding process is stringent enough to discriminate between closely related 
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codons and yet relaxed enough to allow decoding of more than one codon (El 
Yacoubi et al., 2012). Some aminoacyl-tRNA synthetases recognize their cognate 
tRNA’s identity through the structure and chemistry contributed by modified 
nucleotides, particularly within the anticodon domain (Giegé et al., 1998). 
Modifications at position 34 contribute to translation fidelity by ensuring codon 
discrimination by tRNAs. In fact, all tRNA decoding strategies depend heavily on 
modifications at position 34 (Grosjean et al., 2010). Position 37 is also often 
modified. As a rule, when position 36 is an A or U, position 37 is modified. These 
modifications stabilize the first base pair of the codon-anticodon interaction, 
especially A:U and U:A pairs, and thereby contributes to accurate decoding by 
reducing frameshifts (Grosjean et al., 1976). 
The tRNAs most affected by individual and combinations of modifications 
correspond to codons in mixed codon boxes where distinction of the third codon 
base is important for discriminating between the correct cognate or wobble codons 
and the incorrect near‐cognate codons (e.g. AAA/G for lysine versus AAU/C 
asparagine) (Agris, 2004). 
In Saccharomyces cerevisiae, a specific tRNA modifying enzyme (tRNA 
methyltransferase 9 (Trm9)) was identified as a potential enhancer of the DNA 
damage response(Begley et al., 2002, 2004). Therefore, tRNA modifying enzymes 
may also be implicated in genome integrity functions. 
 
1.7. tRNA modifying enzymes and Human diseases 
Only a limited number of tRNA modifying enzymes have been biochemically 
characterized, and most of these are from Escherichia coli and S. cerevisiae 
(Garcia and Goodenough-Lashua, 1998). tRNA modifying enzymes are 
characterized and usually named after the type of modification that they catalyze. 
Previous studies have focused on these modifications as well as the proteins 
responsible for such modifications and their encoding genes (Torres et al., 2014). 
Recent evidence (Abbott et al., 2014; Torres et al., 2014) indicates that tRNA 
modifications and tRNA modifying enzymes may play important roles in complex 
human diseases, namely cancer, neurological disorders and mitochondrial-linked 
disorders (Figure 9). 
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Figure 9 – Human diseases associated with tRNA modifications (Torres et al., 2014). 
 
Several tRNA methyltransferases are fused to DNA repair enzymes, which 
means that these enzymes are directly related to DNA repair and carcinogenesis 
(Begley et al., 2007; Fu et al., 2010; Shimada et al., 2009). 
Some diseases like intellectual disability are associated with mutations in 
genes that encode tRNA modifying enzymes. Others, like cancer, are associated 
with aberrant expression of tRNA modifying enzymes (Torres et al., 2014).  For 
example, FtsJ RNA methyltransferase homolog 1 (FTSJ1) is a gene encoding a 
methyltransferase acting at positions 32 and 34 on some tRNAs (Torres et al., 
2014) that is mutated in patients with non-syndromic X-linked mental retardation 
(Takano et al., 2008). NSUN2 is a gene encoding a methyltransferase (cytosine-5 
tRNA methyltransferase) that is expressed at low levels in normal tissues, but it is 
abundant in a range of Human tumor types (Frye and Watt, 2006). Another 
example of a pathology linked to mutations in NSUN2 is microcephaly. This 
mutation leads to a site-specific loss of m5C modification in tRNAs (Blanco et al., 
2014). The loss of NSUN2 orthologue in Drosophila causes severe short-term 
memory deficits (Abbasi-Moheb et al., 2012). The deletion of cytosine-5 tRNA 
methyltransferases in yeast, flies, fish and mice is not lethal, nevertheless, loss of 
certain tRNA modifications (e.g. Trm9 and Dnmt2) can increase sensitivity to 
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stress stimuli, including drugs, DNA damage or environmental cues (Begley et al., 
2007; Jablonowski et al., 2006; Schaefer et al., 2010). Moreover, Trm9 has also 
been hypothesized as essential for translation fidelity in yeast, as Trm9 deficient 
cells showed an increase in translation infidelity (Patil et al., 2012). Additionally, 
other methyltransferases, Trm4 (which is homologue of human NSUN2 (Okamoto 
et al., 2014)) and Trm8, are found to be essential for cell viability under heat 
stress. tRNAs without modifications by Trm4 and Trm8 are found by the tRNA 
surveillance system and follow a rapid tRNA degradation pathway to decay these 
non-modified tRNAs, leading to cell death (Alexandrov et al., 2006; Whipple et al., 
2011). Lack of translation fidelity is connected to aberrant protein production, 
which is connected to cell death and disease phenotype (Abbott et al., 2014).  
As introduced above, the modifications in the anticodon loop are especially 
important in translation. This notion is particularly significant given that these tRNA 
modifications might affect the translation of only a subset of transcripts enriched in 
certain types of codons. Therefore, codon usage may differ in diseases that are 
associated with deregulations in these tRNA modifying enzymes. 
 
1.8. DNA microarrays 
The DNA microarray technology is a high-capacity system capable of 
monitoring the expression of many genes in parallel (Schena et al., 1995). 
Generally, this is achieved by arraying a large number of cDNA fluorescent probes 
to the surface of a small glass microscope slide, each matching a unique (part of 
a) gene in the genome, to which one or more labeled cDNA samples from cells or 
tissues of interest are hybridized (van Bakel and Holstege, 2008). By examining 
the expression of so many genes simultaneously, it is possible to identify and 
study the gene expression patterns that underlie cell physiology. For example, it is 
possible to assess which genes are switched on (or off) as cells grow, divide, 
differentiate, or respond to hormones or to toxins (Alberts et al., 2008). 
Furthermore, this high-throughput technique has been currently adopted in the 
evaluation of gene expression in cancer cells (Alberts et al., 2008; Begley et al., 
2013; Chin et al., 2011; Corley, 2004; Rhodes et al., 2004; Venet et al., 2011). 
Chapter I 
37 
 
The analysis of microarray data is computationally intensive (Corley, a guide to 
methods biomedical sciences). Nevertheless, nowadays, the statistical 
methodology for microarray analysis has suffered a great progress, from the 
development of novel algorithms to the cluster analysis, which allows the 
identification of genes that share its expression patterns, i.e., that are coordinately 
regulated (Alberts et al., 2008). 
 
1.9. Meta-analysis 
Improvements in microarray technology and its increasing use led to the 
generation of many highly complex datasets that often try to address similar 
biological questions (Ramasamy et al., 2008). Gene expression profiling with 
microarrays has become a standard method for identifying the genes and 
biological pathways that are associated with various complex diseases (Bauer et 
al., 2009; Kim et al., 2014). Thus, it is important to use and make sense of all the 
high throughput data publicly available from such studies. 
The classical definition of meta-analysis is the use of statistical techniques to 
combine results from independent but related studies. However, the classical 
definition has evolved and the term meta-analysis is also widely used to describe 
the whole study process, from the information gathering to data processing 
techniques (Ramasamy et al., 2008). 
The meta-analysis is a relatively inexpensive option, since it makes 
comprehensive use of already available data that has the potential to increase 
both the statistical power and reliability of results. 
For all these advantages, the meta-analysis, and particularly the meta-analysis 
of gene expression microarray datasets, has become an essential tool for 
interpreting the biological data generated by high throughput techniques such as 
microarrays (Kim et al., 2007; Lee et al., 2004; Rhodes et al., 2004). 
The first step to do a meta-analysis is to formulate the objectives and obtain 
the information for our study. In this particular case we need to obtain the gene 
expression information and, for that, we must search a variety of public available 
microarray data repositories. The information must then be extracted from the 
elected repository (or repositories) and the individual datasets prepared in order to 
comprise the information. The preparation of individual datasets includes all the 
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procedures to reduce the technical defects created by the technique in order to 
minimize these defects and assure a quality study. Identification and removal of 
any arrays with poor quality, aggregation of any technical replicates and filter out 
probes with poor quality in the arrays are normal procedures for dataset quality 
control (Ramasamy et al., 2008). It is useful to inspect the datasets for annotations 
as annotations like GeneID are important for further analysis and cross data 
between computer tools and databases. Once all the information is gathered and 
prepared, one can proceed to perform several bioinformatics and statistical 
analysis using computer tools in order to get some insight regarding the objectives 
formulated at the beginning of the study. To complete the meta-analysis, one must 
interpret the results, always considering the strength of evidence and limitations of 
the current findings (Ramasamy et al., 2008). 
 
1.10. Dataset rearrangements – Specific studies: Colorectal cancer gene 
set and CTU2 case study gene set 
Like described before, the first step of a meta-analysis is to formulate the 
objectives and obtain the information. Based on these principles we can establish 
guidelines and construct an experimental design. Our meta-analysis is based on 
microarray gene expression datasets of cancer. From all the diseases connected 
to deregulation of tRNA modifying enzymes, cancer stood out as the disease with 
more available public datasets on various repositories and it has also dedicated 
bioinformatic tools and repositories to cross-link these studies.  
However, every study is singular, and although guidelines can be drawn, we 
must adapt them to take into account the information that we obtain. In our specific 
case, we took that into consideration and created two additional arrays of 
datasets. One of those arrays is comprised of colorectal datasets that were 
obtained from our search. Colorectal cancer was the most represented type of 
cancer on our datasets. Moreover, this type of cancer is the third cause of death 
by cancer in the world and it is the second more incident cancer in Portugal with a 
high mortality rate (Ferlay et al., 2015). 
The other array is comprised of datasets where a specific tRNA modifying 
enzyme (CTU2) was found deregulated. The CTU2 is responsible for modifying 
Chapter I 
39 
 
the wobble base (U34) of lysine (Lys), glutamic acid (Glu) and glutamine (Gln) 
(Schlieker et al., 2008). The uridine at the wobble base of these tRNAs is 
universally modified by thiolation to 5-methyl-2-thiouridine derivatives which 
enhance codon reading accuracy (Björk et al., 2007). 
This thiolation of the wobble uridine (S2U) at position 34 in tRNA-Lys UUU, 
tRNA-Glu UUC, and tRNA-Gln UUG is conserved in nearly all species (Ikeuchi et 
al., 2006). Lysine, glutamic acid and glutamine are encoded by two degenerate 
codons ending in purine in the two-codon boxes. The codons on these boxes 
specify two aminoacids difference in the third bases in the genetic code. The 
corresponding tRNAs decode codons of the type NAA and wobble onto NAG. The 
thiolation of the wobble base on position 2, together with the addition of 
methoxycarbonylmethyl on position 5 (mcm5S2U), was proposed to facilitate and 
restrict base pairing with purines and to prevent incorrect decoding (Ikeuchi et al., 
2006; Krüger et al., 1998; Yarian et al., 2002) 
We focused on CTU2 because it affects specific tRNAs in human and we found 
many dataset where this enzyme was deregulated. For its specific action on the 
wobble position and for its importance on the decoding stringency and therefore 
fidelity, it stands as a good case study to analyze the codon usage on the 
mentioned datasets. 
 
1.11. Aims of the study 
The present study was thought to bridge the current knowledge about the tRNA 
modifying enzymes and certain human diseases, namely cancer, that are linked to 
gene expression deregulations of those enzymes. We seek a relationship between 
the deregulation of tRNA modifying enzymes on cancer and codon usage bias and 
patterns of the remaining deregulated genes. For this matter, we assessed a wide 
number of datasets of various types of cancer through the adoption of 
computational tools and statistical meta-analysis. 
This work can lead to new insights on codon usage patterns and preferences in 
cancer and shed new light on a time when we need to find effective ways to make 
some sense of high throughput data that, otherwise, will never reach their full 
potential.
  
  
 
 
 
 
 
 
 
Chapter II 
 
 
 
 
 
Methodology
  
 
 
Chapter II 
43 
 
2. Methodology 
2.1. Dataset collection and preprocessing 
A list of genes encoding Human tRNA modifying enzymes was elaborated 
based on previous studies describing tRNA modifications and their possible 
implications in Human diseases (Abbott et al., 2014; Torres et al., 2014). 
Once that information was gathered, we searched each gene of that list on 
OncomineTM (http://www.oncomine.com), a cancer microarray database that 
combines three general data layers: data input, data analysis and data 
visualization (Figure 10). 
 
Figure 10 – Oncomine
TM
 layout (adapted from Rhodes et al., 2007). 
 
The OncomineTM uses the stored datasets collected from cancer microarray 
studies from published literature and allow us to search datasets for a specific 
gene of interest and see if it is deregulated and in which type or subtype of cancer 
that deregulation occurs. The analysis can be performed focused on a specific 
tissue and comparison type (e.g., breast cancer vs normal) and/or a particular 
analysis type (e.g., differential expression). These tools allow us to perform a 
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differential analysis of various types and subtypes of cancer and that can be done 
for a specific gene or dataset of interest. It is therefore a very useful tool that 
facilitates the answer of targeted biological questions of the collective 
transcriptome dataset (Rhodes et al., 2007). The OncomineTM platform was used 
as a mean to narrow our search. With this method we managed to retain only 
datasets where tRNA modifying enzymes were deregulated and a list comprising 
those enzymes was created. We carried out a differential analysis, Cancer vs. 
Normal Analysis, intending to evaluate the differences in expression between 
numerous cancer types and normal tissues. 
The lists of datasets as well as deregulated enzymes in cancer resulted from 
this search were used in posterior analysis. 
 
2.2.  Dataset retrieving 
The datasets that contain deregulations on genes encoding tRNA modifying 
enzymes were assessed on Gene Expression Omnibus (GEO) 
(http://www.ncbi.nlm.nih.gov/geo/) and analyzed using the GEO2R (GEO’s online 
tool for analyzing GEO data (available at http://www.nci.nlm.nih.gov/geo/geo2r/). 
GEO2R is an interactive online tool for R-based analysis of GEO data and it’s 
used to identify genes that are differentially expressed across experimental 
conditions. The Benjamini & Hochberg false discovery rate method is used to 
apply P-value adjustment for multiple-testing correction. The same analytical tool 
was used for each dataset individually to maintain consistency during individual 
analysis.  
The test samples were selected according to the same selection done by the 
OncomineTM and computed into two groups, a group containing normal tissue 
samples and another one composed of cancer tissue. This measure was applied 
to certify that the generated GEO2R results corresponded exactly to the ones on 
OncomineTM. The output processed by GEO2R was then stripped of eventual 
background “noise” values, for that, the expression values, whose p-value was 
higher than 0.05, were discarded. 
After these analyses we merged all gene expression data for all the datasets 
and extracted a list of genes corresponding to both up-regulated gene expression 
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data and down-regulated data. These lists were comprised only by genes up-
regulated or down-regulated present on most of the datasets. The criterion used 
for the selection of each gene was its presence in at least 90% of the datasets. We 
considered any gene whose expression exceeded an M-value of 0.5 to be up-
regulated and, conversely, any gene whose expression was below the value of -
0.5. Moreover, all genes whose statistical significance was above p-value 0.1 were 
excluded. 
In parallel, we merged all gene expression data for the colorectal datasets in 
one array of datasets and we also merged all datasets where CTU2 tRNA 
modifying enzyme was found deregulated. For both cases we adopted the same 
methodology described above and below. 
 
2.3. GO enrichment analysis 
A preliminary gene ontology (GO) enrichment analysis was performed to 
evaluate if there were any GO enriched categories on each of those groups. For 
this analysis we used the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) v6.7 (http://david.abcc.ncifcrf.gov/home.jsp). In this work we 
only used the functional annotation tool and we focused on the GO, therefore, all 
the other default checked category boxes were unchecked. The function 
annotation tool was always used as a view tool for selected annotation. 
 
2.4.  Sequence retrieving 
The up-regulated and down-regulated gene sequences were downloaded from 
Ensembl (http://www.ensembl.org) Biomart tool, using the Ensembl gene release 
78. Ensembl is a genomic interpretation system providing the most up-to-date 
annotations, querying tools and access methods for chordates and key model 
organisms (Cunningham et al., 2015). 
The coding sequences were retrieved by submitting the associated gene name 
as the external reference ID input list. The filters and attributes were applied in 
order to exclude all the associated transcript ID and sequences information. 
 
 
Methodology 
46 
 
2.5. Sequence analysis 
All downloaded sequences for every group and type of analysis were loaded 
and analyzed on ANACONDA® (version 2.0), which is a software package 
developed for gene primary structure analysis (Moura et al., 2005, 2008). It uses 
gene sequences downloaded from public databases and applies a set of statistical 
and visualization methods in different ways, to reveal information about codon 
context, codon usage, nucleotide repeats within open reading frames (ORFeome) 
and others. 
The ORFeome analysis gives information regarding codon usage; codon 
frequency; amino acid properties; among others, for every codon in each gene. A 
normalized codon frequency ratio was calculated for each codon of every gene, 
and that information was clustered using a hierarchical clustering method (single 
linkage) implemented in Cluster 3.0 software 
(http://bonsai.hgc.jp/~mdehoon/software/cluster). The cluster results were 
visualized by the TreeView program (http://rana.lbl.gov/EisenSoftware.htm). 
The codon usage bias was measured by using codon adaptation index (CAI), 
and the frequency of the nucleotide G+C at the synonymous third codon position 
(GC3). 
CAI (Sharp and Li, 1987) is used to estimate the degree of bias toward codons 
in highly expressed genes and thus assesses the effective selection which helps in 
shaping the codon usage pattern (Naya et al., 2001). The CAI ranges from 0 to 1, 
for a gene in which all synonymous codons are used equally, the value would be 0 
for no bias while only optimal codons are used, value will be 1 for strongest bias 
(Sharp and Li, 1987). 
GC3 is a good indicator of the extent of base composition bias (Zhou et al., 
2005). Since base composition bias, namely GC, has a major influence on codon 
bias in human (Palidwor et al., 2010), this indicator can be used as a codon usage 
index. 
 
2.6. Statistical analysis 
The statistical analysis was performed on R (https://www.r-project.org/). R is a 
language and environment for statistical computing and graphics that is available 
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as free software and provides a wide variety of statistical and graphical techniques 
(R Development Core Team, 2013). 
A covariance biplot was performed according to Gabriel (1971). The 
covariance biplot is a visualization technique that, as the standard Principal 
Component Analysis (PCA), projects complex sets of data in a narrow dimensional 
space and facilitates pattern visualization. However, when data are binary, like 
those obtained in the analysis of molecular information, standard PCA is not 
suitable because the response along the dimensions is linear (Demey et al., 
2008). Thus, the covariance biplot gives a better answer to binary data where 
there is a variable dependent group clustering. 
The covariance biplot was performed with the information of the ORFeome 
analysis. The computed information excluded all the stop codons since they have 
no associated tRNA and thus should not exhibit codon usage bias (Heizer et al., 
2006). 
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3. Results 
3.1. Data overview 
A total of 37 main datasets were used in this study and, since some of those 
contained different subtypes of cancer, a new dataset was generated for each 
cancer subtype, leading to an expansion of the original number to 70 datasets. 
Our data is comprised of 17 different types of cancer, namely, bladder, brain, 
cervical, colorectal, esophageal, gastric, head and neck, kidney, leukemia, liver, 
lung, lymphoma, melanoma, myeloma, ovarian, sarcoma and other types of 
cancer that have been included on a category by the same designation (Table 1). 
The colorectal cancer is the more representative cancer amongst our datasets 
(Table 1). 
 
Table 1 – Cancer types and number of datasets used in the study. 
 
 
From these 70 datasets, a total of 36 different tRNA modifying enzymes were 
found deregulated, scattered by all the 17 different types of cancer. In general, 
cervical and colorectal cancer datasets presented the highest number of 
deregulated tRNA modifying enzymes. On the other hand, sarcoma and 
Cancer Types Number of Datasets
Bladder cancer 2
Brain and CNS cancer 5
Cervical cancer 4
Colorectal cancer 16
Esophageal cancer 2
Gastric cancer 5
Head and neck 2
Kidney 6
Leukemia 3
Liver cancer 3
Lung cancer 4
Lymphoma 2
Melanoma 2
Myeloma 4
Other cancer 3
Ovarian cancer 1
Sarcoma 6
Total 70
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esophageal cancer datasets showed the opposite pattern concerning deregulated 
tRNA modifying enzymes (Figure 11). Additional information concerning each 
dataset and its corresponding GEO accession code is provided on the 
supplementary material (Suppl. Table I).   
 
 
 
 
Figure 11 – Number of deregulated tRNA modifying enzymes in each cancer type dataset. 
Each bar corresponds to a cancer type and the cancer type with the highest number of 
deregulated enzymes is colorectal cancer. Conversely, the cancer type with the lowest 
number of deregulated enzymes is esophageal cancer. Apart from colorectal cancer, the 
cancer types with more deregulated enzymes are cervical cancer and myeloma. 
 
3.2. GO enrichment analysis 
The data collected pointed to different GO enriched categories between up-
regulated and down-regulated genes. These results were observed both among 
the datasets corresponding to all different types of cancer, datasets corresponding 
only to colorectal cancer and datasets where CTU2 was found deregulated. In the 
up-regulated genes (Tables 2, 4 and 6) the most enriched GO groups are related 
to cell proliferation (e.g. cell cycle processes, mitosis, cell division) and the most 
enriched GO groups on down-regulated genes are related to cell differentiation 
functions (e.g. cell homeostasis and ion homeostasis) (Tables 3, 5 and 7). 
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Table 2 – GO enrichment analysis of up-regulated genes from all cancer datasets. The most 
enriched GO groups are related to cell proliferation functions (e.g. cell cycle, mitosis and 
cell division). 
 
 
 
Table 3 – GO enrichment analysis of down-regulated genes from all cancer datasets. The 
most enriched GO groups on down-regulated genes are related to cell differentiation 
functions (e.g. chemical homeostasis and ion homeostasis). 
 
 
 
Cluster A Enrichment Score: 52.8
Term Count % PValue List Total Fold Enrichment FDR
GO:0007049~cell cycle 81 48.21 5.88E-59 153 9.23 9.38E-56
GO:0000279~M phase 61 36.31 1.04E-57 153 16.39 1.66E-54
GO:0022403~cell cycle phase 65 38.69 4.55E-57 153 13.88 7.25E-54
GO:0000278~mitotic cell cycle 61 36.31 1.76E-54 153 14.58 2.80E-51
GO:0022402~cell cycle process 69 41.07 1.95E-53 153 10.80 3.11E-50
GO:0007067~mitosis 51 30.36 1.16E-52 153 20.50 1.84E-49
GO:0000280~nuclear division 51 30.36 1.16E-52 153 20.50 1.84E-49
GO:0000087~M phase of mitotic cell cycle 51 30.36 3.10E-52 153 20.13 4.95E-49
GO:0048285~organelle fission 51 30.36 1.04E-51 153 19.69 1.65E-48
GO:0051301~cell division 50 29.76 2.02E-44 153 14.99 3.22E-41
Cluster B Enrichment Score: 26.4
Term Count % PValue List Total Fold Enrichment FDR
GO:0006260~DNA replication 35 20.83 1.11E-31 153 16.29 1.78E-28
GO:0006259~DNA metabolic process 47 27.98 1.53E-29 153 8.21 2.44E-26
GO:0005654~nucleoplasm 47 27.98 3.40E-20 140 4.87 4.29E-17
Cluster A Enrichment Score: 5.4
Term Count % PValue List Total Fold Enrichment FDR
GO:0005576~extracellular region 46 26.14 1.43E-06 143 2.05 1.82E-03
GO:0044421~extracellular region part 29 16.48 1.93E-06 143 2.70 2.45E-03
GO:0005615~extracellular space 22 12.50 2.14E-05 143 2.87 2.72E-02
Cluster B Enrichment Score: 3.1
Term Count % PValue List Total Fold Enrichment FDR
GO:0048878~chemical homeostasis 19 10.80 8.27E-06 145 3.46 1.37E-02
GO:0030003~cellular cation homeostasis 13 7.39 1.71E-05 145 4.78 2.84E-02
GO:0006873~cellular ion homeostasis 15 8.52 4.53E-05 145 3.74 7.53E-02
GO:0006875~cellular metal ion homeostasis 11 6.25 4.63E-05 145 5.24 7.68E-02
GO:0055082~cellular chemical homeostasis 15 8.52 5.38E-05 145 3.68 8.94E-02
GO:0055080~cation homeostasis 13 7.39 5.48E-05 145 4.24 9.10E-02
GO:0055065~metal ion homeostasis 11 6.25 6.75E-05 145 5.01 1.12E-01
GO:0050801~ion homeostasis 15 8.52 1.18E-04 145 3.42 1.96E-01
GO:0030005~cellular di-, tri-valent inorganic cation homeostasis 11 6.25 1.57E-04 145 4.52 2.60E-01
GO:0055066~di-, tri-valent inorganic cation homeostasis 11 6.25 2.38E-04 145 4.29 3.95E-01
GO:0042592~homeostatic process 20 11.36 3.83E-04 145 2.48 6.34E-01
GO:0019725~cellular homeostasis 15 8.52 4.49E-04 145 3.00 7.43E-01
GO:0006874~cellular calcium ion homeostasis 9 5.11 7.58E-04 145 4.59 1.25E+00
GO:0055074~calcium ion homeostasis 9 5.11 9.03E-04 145 4.47 1.49E+00
GO:0051480~cytosolic calcium ion homeostasis 5 2.84 3.72E-02 145 3.95 4.68E+01
GO:0008015~blood circulation 6 3.41 4.87E-02 145 3.01 5.63E+01
GO:0003013~circulatory system process 6 3.41 4.87E-02 145 3.01 5.63E+01
GO:0008016~regulation of heart contraction 4 2.27 4.89E-02 145 4.85 5.65E+01
GO:0051241~negative regulation of multicellular organismal process 4 2.27 2.54E-01 145 2.28 9.92E+01
GO:0007186~G-protein coupled receptor protein signaling pathway 11 6.25 7.66E-01 145 0.91 1.00E+02
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Table 4 – GO enrichment analysis of up-regulated genes from colorectal cancer datasets. 
The most enriched GO groups are related to cell proliferation functions (e.g. cell cycle 
phase, mitosis and nuclear division). 
 
 
 
Table 5 – GO enrichment analysis of down-regulated genes from colorectal cancer datasets. 
The most enriched GO groups on down-regulated genes are related to cell differentiation 
functions (e.g. positive regulation of signal transduction and ion homeostasis). 
 
  
Cluster A Enrichment Score: 18.8
Term Count % PValue List Total Fold Enrichment FDR
GO:0031981~nuclear lumen 162 18.60 9.15E-26 619 2.31 1.30E-22
GO:0043233~organelle lumen 185 21.24 8.29E-25 619 2.10 1.18E-21
GO:0070013~intracellular organelle lumen 182 20.90 1.11E-24 619 2.11 1.59E-21
GO:0031974~membrane-enclosed lumen 187 21.47 1.19E-24 619 2.08 1.70E-21
GO:0005730~nucleolus 85 9.76 3.69E-15 619 2.51 5.22E-12
GO:0043228~non-membrane-bounded organelle 204 23.42 4.45E-14 619 1.62 6.35E-11
GO:0043232~intracellular non-membrane-bounded organelle 204 23.42 4.45E-14 619 1.62 6.35E-11
GO:0005654~nucleoplasm 94 10.79 3.66E-13 619 2.20 5.22E-10
Cluster B Enrichment Score: 15.7
Term Count % PValue List Total Fold Enrichment FDR
GO:0022403~cell cycle phase 71 8.15 4.10E-20 671 3.46 7.30E-17
GO:0000279~M phase 62 7.12 1.11E-19 671 3.80 1.96E-16
GO:0022402~cell cycle process 83 9.53 3.87E-19 671 2.96 6.88E-16
GO:0007049~cell cycle 96 11.02 5.53E-17 671 2.49 9.84E-14
GO:0000278~mitotic cell cycle 61 7.00 1.67E-16 671 3.32 4.00E-13
GO:0000280~nuclear division 44 5.05 5.66E-15 671 4.03 1.01E-11
GO:0007067~mitosis 44 5.05 5.66E-15 671 4.03 1.01E-11
GO:0000087~M phase of mitotic cell cycle 44 5.05 1.11E-14 671 3.96 1.97E-11
GO:0048285~organelle fission 44 5.05 2.51E-14 671 3.87 4.46E-11
GO:0051301~cell division 49 5.63 2.23E-13 671 3.35 3.96E-10
Cluster A Enrichment Score: 4.0
Term Count % PValue List Total Fold Enrichment FDR
GO:0010627~regulation of protein kinase cascade 30 3.70 1.16E-06 586 2.78 2.07E-03
GO:0009967~positive regulation of signal transduction 31 3.82 1.23E-05 586 2.43 2.18E-02
GO:0010647~positive regulation of cell communication 31 3.82 9.54E-05 586 2.18 1.70E-01
GO:0010740~positive regulation of protein kinase cascade 20 2.47 1.11E-04 586 2.76 1.97E-01
GO:0043122~regulation of I-kappaB kinase/NF-kappaB cascade 13 1.60 2.23E-03 586 2.80 3.90E+00
GO:0043123~positive regulation of I-kappaB kinase/NF-kappaB cascade 12 1.48 3.07E-03 586 2.86 5.34E+00
Cluster B Enrichment Score: 3.1
Term Count % PValue List Total Fold Enrichment FDR
GO:0050801~ion homeostasis 39 4.81 7.46E-06 586 2.20 1.33E-02
GO:0055082~cellular chemical homeostasis 36 4.44 2.06E-05 586 2.19 3.66E-02
GO:0006873~cellular ion homeostasis 35 4.32 3.52E-05 586 2.16 6.27E-02
GO:0055080~cation homeostasis 29 3.58 4.70E-05 586 2.34 8.36E-02
GO:0048878~chemical homeostasis 43 5.30 5.10E-05 586 1.94 9.07E-02
GO:0019725~cellular homeostasis 40 4.93 6.10E-05 586 1.98 1.09E-01
GO:0042592~homeostatic process 55 6.78 1.56E-04 586 1.69 2.77E-01
GO:0030003~cellular cation homeostasis 25 3.08 2.76E-04 586 2.27 4.91E-01
GO:0006875~cellular metal ion homeostasis 19 2.34 2.13E-03 586 2.24 3.72E+00
GO:0055065~metal ion homeostasis 19 2.34 3.46E-03 586 2.14 5.99E+00
GO:0055066~di-, tri-valent inorganic cation homeostasis 21 2.59 3.69E-03 586 2.03 6.37E+00
GO:0030005~cellular di-, tri-valent inorganic cation homeostasis 20 2.47 4.57E-03 586 2.03 7.84E+00
GO:0006874~cellular calcium ion homeostasis 15 1.85 2.77E-02 586 1.89 3.94E+01
GO:0055074~calcium ion homeostasis 15 1.85 3.38E-02 586 1.84 4.58E+01
GO:0007204~elevation of cytosolic calcium ion concentration 10 1.23 4.87E-02 586 2.10 5.89E+01
GO:0051480~cytosolic calcium ion homeostasis 10 1.23 6.97E-02 586 1.96 7.24E+01
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Table 6 – GO enrichment analysis of up-regulated genes from cancer datasets where CTU2 
was found deregulated. The most enriched GO groups are related to cell proliferation 
functions (e.g. cell cycle phase, mitosis and cell division). 
 
 
 
Table 7 – GO enrichment analysis of down-regulated genes from cancer datasets where 
CTU2 was found deregulated. The most enriched GO groups on down-regulated genes are 
related to cell differentiation functions (e.g. chemical homeostasis and homeostatic 
process). 
 
Cluster A Enrichment Score: 16.3
Term Count % PValue List Total Fold Enrichment FDR
GO:0022403~cell cycle phase 56 9.79 3.80E-19 447 4.09 6.60E-16
GO:0007049~cell cycle 78 13.64 8.89E-19 447 3.04 1.54E-15
GO:0000278~mitotic cell cycle 51 8.92 8.51E-18 447 4.17 1.48E-14
GO:0022402~cell cycle process 63 11.01 2.68E-17 447 3.37 4.65E-14
GO:0000279~M phase 47 8.22 4.98E-17 447 4.32 8.64E-14
GO:0007067~mitosis 38 6.64 1.58E-16 447 5.23 1.89E-13
GO:0000280~nuclear division 38 6.64 1.58E-16 447 5.23 1.89E-13
GO:0000087~M phase of mitotic cell cycle 38 6.64 2.88E-16 447 5.13 5.77E-13
GO:0048285~organelle fission 38 6.64 7.10E-16 447 5.02 1.15E-12
GO:0051301~cell division 42 7.34 4.09E-15 447 4.31 7.14E-12
Cluster B Enrichment Score: 15.4
Term Count % PValue List Total Fold Enrichment FDR
GO:0031981~nuclear lumen 118 20.63 3.35E-22 413 2.52 4.70E-19
GO:0070013~intracellular organelle lumen 128 22.38 1.36E-19 413 2.23 1.90E-16
GO:0043233~organelle lumen 129 22.55 3.27E-19 413 2.19 4.59E-16
GO:0031974~membrane-enclosed lumen 130 22.73 6.10E-19 413 2.17 8.56E-16
GO:0043232~intracellular non-membrane-bounded organelle 147 25.70 3.00E-13 413 1.75 4.21E-10
GO:0043228~non-membrane-bounded organelle 147 25.70 3.00E-13 413 1.75 4.21E-10
GO:0005730~nucleolus 61 10.66 2.25E-12 413 2.70 3.16E-09
GO:0005654~nucleoplasm 66 11.54 2.14E-10 413 2.32 3.00E-07
Cluster A Enrichment Score: 5.7
Term Count % PValue List Total Fold Enrichment FDR
GO:0050801~ion homeostasis 70 4.45 8.97E-09 1125 2.06 1.64E-05
GO:0048878~chemical homeostasis 82 5.22 9.53E-09 1125 1.93 1.74E-05
GO:0055082~cellular chemical homeostasis 66 4.20 1.41E-08 1125 2.09 2.57E-05
GO:0006873~cellular ion homeostasis 65 4.13 1.79E-08 1125 2.09 3.26E-05
GO:0055080~cation homeostasis 53 3.37 5.33E-08 1125 2.23 9.73E-05
GO:0030003~cellular cation homeostasis 48 3.05 1.35E-07 1125 2.27 2.46E-04
GO:0006875~cellular metal ion homeostasis 38 2.42 1.75E-06 1125 2.33 3.19E-03
GO:0055065~metal ion homeostasis 39 2.48 2.02E-06 1125 2.29 3.69E-03
GO:0019725~cellular homeostasis 69 4.39 3.03E-06 1125 1.78 5.54E-03
GO:0030005~cellular di-, tri-valent inorganic cation homeostasis 41 2.61 4.07E-06 1125 2.17 7.44E-03
GO:0055066~di-, tri-valent inorganic cation homeostasis 42 2.67 6.17E-06 1125 2.11 1.13E-02
GO:0042592~homeostatic process 98 6.23 6.57E-06 1125 1.57 1.20E-02
GO:0006874~cellular calcium ion homeostasis 33 2.10 4.27E-05 1125 2.17 7.79E-02
GO:0055074~calcium ion homeostasis 33 2.10 7.31E-05 1125 2.11 1.33E-01
GO:0051480~cytosolic calcium ion homeostasis 20 1.27 3.84E-03 1125 2.04 6.79E+00
GO:0007204~elevation of cytosolic calcium ion concentration 18 1.15 9.12E-03 1125 1.97 1.54E+01
Cluster B Enrichment Score: 4.3
Term Count % PValue List Total Fold Enrichment FDR
GO:0006811~ion transport 109 6.93 2.56E-08 1125 1.71 4.68E-05
GO:0006812~cation transport 79 5.03 2.16E-06 1125 1.72 3.95E-03
GO:0030001~metal ion transport 66 4.20 2.06E-05 1125 1.71 3.76E-02
GO:0006814~sodium ion transport 27 1.72 2.07E-05 1125 2.50 3.78E-02
GO:0031402~sodium ion binding 24 1.53 1.38E-04 1119 2.38 2.22E-01
GO:0015672~monovalent inorganic cation transport 46 2.93 2.85E-04 1125 1.74 5.19E-01
GO:0031420~alkali metal ion binding 34 2.16 2.14E-03 1119 1.73 3.39E+00
GO:0055085~transmembrane transport 61 3.88 3.27E-02 1125 1.29 4.55E+01
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3.3. Codon usage analysis 
3.3.1. Codon usage of all cancer datasets 
Following the Anaconda analysis, the heat maps corresponding to the codon 
usage pattern of the up-regulated and down-regulated genes were obtained by 
Cluster 3.0 and are depicted in Figures 12 and 14. 
The codons are clustered according to their frequency of incorporation; higher 
incorporated codons are represented by different intensity of red colors, the higher 
the frequency, the higher the color intensity. Conversely, the lower incorporated 
codons are represented by different intensity of green colors, the lower the 
frequency, the higher the color intensity. The black spots correspond to values of 
codon frequency considered null. The pattern formed by those colors represents 
the codon usage preference of each gene from these datasets. The sets of genes 
cluster into groups that form the distinct patterns that can be observed on the 
following Figures (12 and 14). In Figure 12, corresponding to up-regulated genes 
in all cancer datasets, we can observe a distribution of codons (columns) 
characterized by codons ending in A and U nucleotides on the left side of the 
panel and, conversely, by codons ending in G and C nucleotides on the right side 
of the panel. A deeper look in this figure shows a higher number of genes that 
incorporate more codons ending in A and U (left side – red) than codons ending in 
G and C (right side-green) and a lower number of genes that incorporate more 
codons ending in G and C (right side – red) than codons ending in A and U (left 
side-green). 
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Figure 12 – Heat map of codon frequencies of up-regulated genes from all cancer datasets. 
The green code corresponds to low frequency codons and the red code corresponds to 
high frequency codons. The rank order correlation was used to determine clusters among 
codons (columns) and genes (rows). Codons ending in A and U nucleotides are clustered 
on the left side of the panel and codons ending in G and C nucleotides are clustered on the 
right side. There is a higher number of genes that incorporate more codons ending in A and 
U than codons ending in G and C. 
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Considering the GC3 indicator for the same set of genes, the resulted 
histogram reveals a GC percentage at the third position lower than 50%, resulting 
in a prevalence of AU ending codons (Figure 13). 
 
 
Figure 13 – Percentage of GC in third position of up-regulated genes in all cancer datasets. 
There is a prevalence of codons with AU nucleotides at the third position in these genes.  
 
In Figure 14 (down-regulated genes in all cancer datasets), a distribution of 
codons (columns) is observed, characterized by codons ending in A and U 
nucleotides, generally on the left side of the panel and, conversely, by codons 
ending in G and C nucleotides, generally on the right side of the panel. 
Additionally, sporadic strips of different patterns are distributed along the panel, 
corresponding to clusters of codons that, even though belonging to groups of 
codons segregated on the sides, have been clustered in a different way, leading to 
a scattered disposition on the heat map. Nevertheless, this scattered position 
follow the same color pattern, showing the same tendency as the codons 
segregated by each side of the panel. A deeper look in this figure shows a lower 
number of genes that incorporate more codons ending in A and U (left side – red) 
than codons ending in G and C (right side-green) and a higher number of genes 
that incorporate more codons ending in G and C (right side – red) than codons 
ending in A and U (left side-green). 
Chapter III 
59 
 
 
Figure 14 – Heat map of codon frequencies of down-regulated genes from all cancer 
datasets. The green code corresponds to low frequency codons and the red code 
corresponds to high frequency codons. The rank order correlation was used to determine 
clusters among codons (columns) and genes (rows). Codons ending in A and U nucleotides 
are, generally, clustered on the left side of the panel and codons ending in G and C 
nucleotides are clustered on the right side. The codons ending in A and U nucleotides are 
the higher frequency codons. There is a higher number of genes that incorporate more 
codons ending in A and U than codons ending in G and C 
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Considering the GC3 indicator for the same set of genes, the resulted 
histogram reveals a GC percentage at the third position higher than 50%, resulting 
in a prevalence of GC ending codons (Figure 15). 
 
Figure 15 – Percentage of GC in third position of down-regulated genes in all cancer 
datasets. There is a preference for GC ending codons on the third codon position in these 
genes.  
 
 
Figure 16 – CAI of up-regulated genes in all cancer datasets. The majority of up-regulated 
genes have a CAI between 0.6 and 0.7. 
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In what regards the CAI analysis, the up-regulated genes revealed a lower 
value of CAI (majority of genes with a CAI between 0.6 and 0.7) (Figure 16) when 
compared with the down-regulated genes (majority of genes with a CAI between 
0.65 and 0.8) (Figure 17). 
 
Figure 17 – CAI of down-regulated genes in all cancer datasets. The majority of down-
regulated genes have a CAI between 0.65 and 0.8. 
 
3.3.2. Codon usage of colorectal cancer datasets 
The codon usage analysis of the colorectal cancer datasets demonstrated 
similar tendencies of codon usage patterns (Figures 18 and 20) and CAI (Figures 
19 and 21), when compared to the same analysis on all cancer datasets. 
However, as up-regulated genes shows a higher number of genes that incorporate 
more codons ending in A and U (Figure 18), there is no clear preference by down-
regulated colorectal genes in what regards the majority of gene preference on last 
codon position (Figure 20). 
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Figure 18 – Heat map of codon frequencies of up-regulated genes from colorectal cancer 
datasets. The green code corresponds to low frequency codons and the red code 
corresponds to high frequency codons. The rank order correlation was used to determine 
clusters among codons (columns) and genes (rows). Codons ending in A and U nucleotides 
are clustered on the left side of the panel and codons ending in G and C nucleotides are 
clustered on the right side. There is a higher number of genes that incorporate more codons 
ending in A and U than codons ending in G and C. 
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Figure 19 – CAI of up-regulated genes in colorectal cancer datasets. The majority of down-
regulated genes have a CAI between 0.6 and 0.8. The vast majority have a CAI between 0.65 
and 0.75. 
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Figure 20 – Heat map of codon frequencies of down-regulated genes from colorectal cancer 
datasets. The green code corresponds to low frequency codons and the red code 
corresponds to high frequency codons. The rank order correlation was used to determine 
clusters among codons (columns) and genes (rows). Codons ending in A and U nucleotides 
are clustered on the left side of the panel and codons ending in G and C nucleotides are 
clustered on the right side. There is no clear preference in what regards the majority of gene 
preference on last codon position. 
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Figure 21 – CAI of down-regulated genes in colorectal cancer datasets. The majority of 
down-regulated genes have a CAI between 0.6 and 0.8. The vast majority have CAIs between 
0.65 and 0.75. 
 
However, the GC percentage on the third position on both up-regulated and 
down-regulated genes is higher than 50% (Figures 22 and 23). Nevertheless, the 
tendency to a higher percentage of GC on the third position in the case of down-
regulated genes when compared to up-regulated genes remained noticeable 
(Figures 22 and 23). 
 
 
Figure 22 – Percentage of GC in third position of up-regulated genes in colorectal cancer 
datasets. There is a preference for codons ending with GC nucleotides at the last codon 
position. However, the percentage of GC at the third position is lower when compared with 
colorectal cancer down-regulated genes.  
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Figure 23 – Percentage of GC in third position of down-regulated genes in colorectal cancer 
datasets. There is a preference for GC ending codons on the third codon position in these 
genes.  
 
3.3.3. Codon usage of cancer datasets with deregulated CTU2 
The heat map in Figure 24, corresponding to up-regulated genes of cancer 
shows a distribution of codons, characterized by codons ending in A and U 
nucleotides on the left side of the panel and, conversely, by codons ending in G 
and C nucleotides on the right side of the panel. As in the group of up-regulated 
genes in all cancer datasets, we can see in this figure that there is a higher 
number of genes that incorporate more codons ending in A and U (left side – red) 
than codons ending in G and C (right side-green) and a lower number of genes 
that incorporate more codons ending in G and C (right side – red) than codons 
ending in A and U (left side-green). 
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Figure 24 – Heat map of codon frequencies of up-regulated genes in cancer datasets where 
CTU2 tRNA modifying enzyme was found deregulated. The green code corresponds to low 
frequency codons and the red code corresponds to high frequency codons. The rank order 
correlation was used to determine clusters among codons (columns) and genes (rows). 
Codons ending in A and U nucleotides are clustered on the left side of the panel and 
codons ending in G and C nucleotides are clustered on the right side. There is a higher 
number of genes that incorporate more codons ending in A and U than codons ending in G 
and C. 
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Figure 25 – Percentage of GC in third position of up-regulated genes in cancer datasets 
where CTU2 tRNA modifying enzyme was found deregulated. There is a preference for AU 
ending codons on the third codon position in these genes. 
 
 
Figure 26 – CAI of up-regulated genes in cancer datasets where CTU2 tRNA modifying 
enzyme was found deregulated. The majority of up-regulated genes have a CAI between 0.6 
and 0.75. The vast majority have CAIs between 0.6 and 0.7. 
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Figure 27 – Heat map of codon frequencies of down-regulated genes in cancer datasets 
where CTU2 tRNA modifying enzyme was found deregulated. The green code corresponds 
to low frequency codons and the red code corresponds to high frequency codons. The rank 
order correlation was used to determine clusters among codons (columns) and genes 
(rows). Codons ending in A and U nucleotides are clustered on the left side of the panel and 
codons ending in G and C nucleotides are clustered on the right side. There is a higher 
number of genes that incorporate more codons ending in G and C than codons ending in A 
and U. 
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Figure 28 – Percentage of GC in third position of down-regulated genes in cancer datasets 
where CTU2 tRNA modifying enzyme was found deregulated. There is a preference for GC 
ending codons on the third codon position in these genes. 
 
 
Figure 29 – CAI of down-regulated genes in cancer datasets where CTU2 tRNA modifying 
enzyme was found deregulated. The majority of down-regulated genes have a CAI between 
0.6 and 0.8. The vast majority have CAIs between 0.65 and 0.75. 
 
3.4. Covariance biplot analysis 
3.4.1. Covariance biplot of all cancer datasets 
The covariance biplot corresponding to the deregulated genes of all cancer 
datasets revealed the existence of two groups, one composed by up-regulated 
genes (red-left side) and another group composed by down-regulated genes 
(green-right side) (Figure 30). Furthermore, the codons (variables) ending in A and 
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U nucleotides, which are represented by arrows, stretch in the direction of the up-
regulated group of genes. Conversely, the codons ending in G and C nucleotides 
stretch in the direction of the up-regulated group of genes.  
 
 
Figure 30 – Covariance biplot of deregulated genes in cancer datasets. Red dots represent 
up-regulated genes and green dots represent down-regulated genes. Each vector 
corresponds to a different codon and are represented in gray. The majority of up-regulated 
genes show a preference for codons ending in A and U nucleotides and the majority of 
down-regulated genes show a preference for codons ending in G and C nucleotides. 
 
We can depict in the Figure 31, a representation of the previous biplot (Figure 
31(A)), as well as two frequency histograms that show the distribution of up-
regulated genes (Figure 31(B)) and down-regulated genes (Figure 31(C)).  
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Figure 31 – (A) Covariance biplot of deregulated genes in cancer datasets. Red dots 
represent up-regulated genes and green dots represent down-regulated genes. Each vector 
corresponds to a different codon and is represented in gray. Distribution of up-regulated (B) 
and down-regulated (C) genes on the first dimension of the covariance biplot; the black bars 
divide the histograms in positive (right side) and negative (left side) sides, according to the 
relative position on the biplot. The majority of up-regulated genes show a preference for 
codons ending in A and U nucleotides and the majority of down-regulated genes show a 
preference for codons ending in G and C nucleotides. 
 
The histograms (Figure 31(B) and (C)) help identifying the two distinct groups 
of genes formed by up-regulated and down-regulated genes. Histogram B (Figure 
31(B)) shows that 77.5% of up-regulated genes are grouped on the left side of the 
biplot according to the 1st dimension of the covariance. Conversely, histogram C 
(Figure 31(C)) shows that 67.5% of the down-regulated genes are grouped on the 
right side of the biplot. 
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3.4.2. Covariance biplot of colorectal cancer datasets 
The covariance biplot corresponding to the deregulated gene of colorectal 
cancer datasets also revealed the existence of two groups: one composed by up-
regulated genes (red-left side) and another group composed by down-regulated 
genes (green-right side).  
 
Figure 32 – Covariance biplot of deregulated genes in colorectal cancer datasets. Red dots 
represent up-regulated genes and green dots represent down-regulated genes. Each vector 
corresponds to a different codon and are represented in gray. The majority of up-regulated 
genes show a preference for codons ending in A and U nucleotides and, in down-regulated 
genes, there is a preference for codons ending in G and C nucleotides. 
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Nevertheless, the separation between those groups is not as clear as the 
results from the deregulated genes of all cancer datasets. This is observable from 
the frequency histogram (Figure 33). 
 
Figure 33 – (A) Covariance biplot of deregulated genes in colorectal cancer datasets. Red 
dots represent up-regulated genes and green dots represent down-regulated genes. Each 
vector corresponds to a different codon and is represented in gray. Distribution of up-
regulated (B) and down-regulated (C) genes on the first dimension of the covariance biplot; 
the black bars divide the histograms in positive (right side) and negative (left side) sides, 
according to the relative position on the biplot. The majority of up-regulated genes show a 
preference for codons ending in A and U nucleotides and, in down-regulated genes, there is 
a preference for codons ending in G and C nucleotides. 
 
The histograms (Figure 33(B) and (C)) help identifying the two distinct groups 
of genes formed by up-regulated and down-regulated genes. Histogram B (Figure 
33(B)) shows that 59.4% of up-regulated genes are grouped on the left side of the 
biplot according to the 1st dimension of the covariance. Conversely, histogram C 
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(Figure 33(C)) shows that 55% of the down-regulated genes are grouped on the 
right side of the biplot. 
 
3.4.3. Covariance biplot of cancer datasets with deregulated CTU2 
The covariance biplot corresponding to the deregulated genes of all cancer 
datasets where CTU2 was found deregulated revealed the existence of two 
groups, one composed by up-regulated genes (red-right side) and another group 
composed by down-regulated genes (green-left side). Furthermore, only codons 
corresponding to the tRNAs specifically modified by the CTU2 were used in this 
analysis. The codons (variables) ending in A nucleotides, which are represented 
by arrows, stretch in the direction of the up-regulated group of genes. Conversely, 
the codons ending in G nucleotides stretch in the direction of the down-regulated 
group of genes (Figure 34). This defines the preference of up-regulated genes for 
codons ending in A (AAA, CAA and GAA) and the preference of down-regulated 
genes for codons ending in G (AAG CAG GAG). 
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Figure 34 – Covariance biplot of deregulated genes in cancer datasets where CTU2 tRNA 
modifying enzyme was found deregulated. Each vector corresponds to Lys (AAA AAG), Glu 
(GAA GAG) and Gln (CAA CAG) codons. CTU2 modifies the tRNA wobble positions of 
tRNA(Lys), tRNA(Glu) and tRNA(Gln). The majority of up-regulated genes show a preference 
for codons ending in A nucleotides and the majority of down-regulated genes show a 
preference for codons ending in G nucleotides. 
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Figure 35 – (A) Covariance biplot of deregulated genes in CTU2 deregulated cancer 
datasets. Red dots represent up-regulated genes and green dots represent down-regulated 
genes. Each vector corresponds to a different codon and are represented in gray. 
Distribution of up-regulated (B) and down-regulated (C) genes on the first dimension of the 
covariance biplot; the black bars divide the histograms in positive (right side) and negative 
(left side) sides, according to the relative position on the biplot. The majority of up-regulated 
genes show a preference for codons ending in A nucleotides and the majority of down-
regulated genes show a preference for codons ending in G nucleotides. 
 
The histograms (Figure 35(B) and (C)) help identifying the two distinct groups 
of genes formed by up-regulated and down-regulated genes. Histogram B (Figure 
33(B)) shows that 62.2% of up-regulated genes are grouped on the left side of the 
biplot according to the 1st dimension of the covariance. Conversely, histogram C 
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(Figure 33(C)) shows that 61.8% of the down-regulated genes are grouped on the 
right side of the biplot. 
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4. Discussion  
4.1. Overview 
tRNA modifying enzymes are essential to the normal function of cells. 
Mutations on genes encoding these enzymes, as well as deregulations at their 
expression levels can compromise cellular fitness, ultimately leading to disease 
phenotypes (Abbott et al., 2014; Torres et al., 2014).  
Aberrant expression of tRNA modifying enzymes has been associated with  
cancer (Torres et al., 2014). Nevertheless, the underlying mechanisms and their 
relationship with this disease are far from being fully understood. 
To the author’s knowledge, this is the first study assessing the relationship 
between deregulated tRNA modifying enzymes and their potential influence as 
modulator factors of codon usage in cancer. Furthermore, this study combines 
publicly available microarray datasets of various cancer types that were thus 
analyzed by the same analytical, statistical and meta-analysis tools. We identified 
and analyzed 37 studies and 70 microarray datasets of various different types and 
subtypes of cancer. 
There are several reasons for the discordance of these studies: differences in 
microarray platforms, quality of microarray results, methods of analysis and 
tissues used for analysis. To compensate, we analyzed every dataset individually 
before proceeding to the meta-analysis tools and, for that, we used the same tool, 
GEO2R, for each and all datasets. We also divided some datasets that contained 
more than one type/subtype of cancer or more than one tissue type to minimize 
the discrepancy between samples. All this proceedings were adopted to minimize 
discordances in the microarray data and to assure a certain degree of confidence 
in the results. 
We decided to create the additional colorectal and CTU2 alternative arrays of 
datasets, in one hand because the colorectal cancer was the most represented 
type of cancer on our datasets, on the other hand because colorectal cancer is the 
third cause of death by cancer in the world and it is the second more incident 
cancer in Portugal with a high mortality rate (Ferlay et al., 2015). 
Additionally, in what regards the CTU2 datasets, we intend with this work to 
shed a new light on the relationship between tRNA modifying enzymes with cancer 
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and how codon usage can be influenced by those enzymes. As the CTU2 tRNA 
modifying enzyme modifies the wobble position of specific tRNAs (tRNA-Lys, 
tRNA-Glu and tRNA-Gln) it is a good starting point to evaluate the codon usage of 
the corresponding codons where that enzyme is deregulated.  
 
4.2. Codon bias variation 
In the present study, a comprehensive analysis of the GC composition in 70 
cancer datasets revealed that there are differences in GC content at the third 
codon position between up-regulated and down-regulated gene sets and this 
seems to influence codon usage bias. In a triplet, the GC contents at the three 
positions are different because these positions have different selective constraints 
(RoyChoudhury and Mukherjee, 2010). 
As GC content is correlated with various genomic features, we can infer repeat 
element distribution and, for instance, methylation pattern (Jabbari and Bernardi, 
1998). Since different genomes have their own characteristic patterns of 
synonymous codon usage, it has not been easy to provide a satisfactory 
explanation for the particular pattern that is found in a given genome (Chen et al., 
2014; Grantham et al., 1980). 
It is suggested that the distribution of GC content in mammals could have 
some functional relevance (Galtier et al., 2001). In fact, that was observed in our 
study, there seems to be a correlation between the GC content and gene function. 
We observed, from our GO enrichment analysis, that clusters of genes involved in 
cell proliferation functions tend to have a lesser GC content on the third codon 
position and those clusters of genes involved in cell differentiation functions tend 
to have a higher GC content of the same codon position. Furthermore, a similar 
tendency was reported in a recent study (Gingold et al., 2014). 
The GC content of synonymous sites correlates positively with levels of gene 
expression (Hershberg and Petrov, 2008) and this indeed seems to be the case in 
our study, as we observe higher levels of CAI in gene sets with higher percentage 
of GC content on the third position. Conversely, our results show lower levels of 
CAI in gene sets with lower percentage of GC content on the third position. 
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CAI is an index of codon adaptation that is used to estimate the degree of bias 
toward codons. The higher the values of this index, the higher will be the bias on 
the respective codon usage. High values of CAI, aside from a higher codon usage 
bias, also indicates that those genes are closer (in terms of codon usage and 
expression levels) to those highly expressed genes used as reference for this 
index (Stenico et al., 1994). Therefore, one should expect a higher CAI in genes 
associated with high expression. 
Our results point to a relationship between higher levels of CAI and high 
percentage of GC content on the third position. One can infer, based on the 
previous observations, that, at least in this particular study, the gene sets that 
present higher numbers of CAI and higher percentage of GC on the third position 
are closer, in terms of codon usage and codon composition, to highly expressed 
human genes. However, all our results show that the gene sets corresponding to 
up-regulated genes have lower CAI and GC content on the third position when 
compared to down-regulated gene sets. In addition, it is known that codon bias is 
positively correlated with gene expression level (Ikemura, 1981). Moreover, highly 
expressed genes may also undergo selection for increased GC content (Lercher et 
al., 2003). Our results show a converse tendency to these principles since the 
gene set that shows higher CAI comprise genes that are down-regulated. 
However, the difference in CAI between the up-regulated and down-regulated 
gene sets is not very high, thus this tendency requires further analysis to prove 
this conclusion. 
Nevertheless, these results demonstrate that, in cancer, the most expressed 
genes follow a different pattern of codon usage when compared to normal tissue. 
 
4.3. GO enrichment analysis 
Given a set of genes that are up-regulated or down-regulated under certain 
conditions, an enrichment analysis will find which GO terms are over-represented 
(or under-represented) using annotations for that gene set. This analysis start by 
mapping a large number of interesting genes in a list to the associated biological 
annotation (e.g. Gene Ontology Terms), and then statistically highlight the most 
over-represented (enriched) biological annotation out of thousands of linked terms 
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and contents. Generically, the term enrichment means that the quantity of genes 
belonging to the specific biological function is more “concentrated” than expected 
by chance. GO enrichment analysis is a particularly important tool when 
processing the vast amount of information in a meta-analysis study as it increases 
the likelihood for investigators to identify biological processes most pertinent to the 
biological phenomena under study (Huang et al., 2009). 
Our results revealed that, the genes that constitute the up-regulated gene sets, 
corresponding to every group of datasets that were made for our meta-analysis, 
are involved in proliferation processes. Not only was it a consistent result, the 
enrichment score of whole most relevant gene clusters formed by the up-regulated 
genes was very high. A higher enrichment score for a group of genes indicates 
that the members (genes) are involved in more important (enriched) roles (Huang 
et al., 2007). 
In fact, it was an expected result. It is well documented, in gene expression 
studies, a generalized increase in expression of genes related with proliferation in 
cancer (Perou et al., 2000; Rosenwald et al., 2003; Venet et al., 2011; Whitfield et 
al., 2006; Yu et al., 2012). 
Furthermore, the genes that constitute the down-regulated gene sets, 
corresponding to every group of datasets that were made for our meta-analysis, 
are involved in differentiation processes. These results are found consistently 
throughout our different arrays of datasets. However, enrichment scores of down-
regulated gene sets are lower when compared to those observed in up-regulated 
gene sets. Despite pointing to consistent results about biological processes, these 
values of enrichment score suggest a more random spread of down-regulated 
genes throughout various biological processes. It has been suggested that codon-
mediated translational control may play an important role in the differentiation and 
regulation of tissue-specific gene products in humans (Plotkin et al., 2004). If in 
fact that is the case, this may explain why we can see these differences in gene 
function between up-regulated and down-regulated genes.  
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4.4. Covariance biplot  
The covariance biplot is a powerful visualization technique that facilitates 
pattern visualization between variables and cases. In our study, the variables are 
codons and the cases are genes. This technique gives a better answer to our set 
of data, since it is binary data, where there is a variable dependent group 
clustering. 
The covariance biplot corresponding to the deregulated genes of all cancer 
datasets revealed the existence of two groups, one composed by up-regulated 
genes (red-right side) and another group composed by down-regulated genes 
(green-left side). Furthermore, the codons ending in A/U and codons ending in 
G/C exhibit a distinct separation behavior, leading to the direction of up-regulated 
genes group and down-regulated genes group, respectively. This defines the 
preference of up-regulated genes for codons ending in A and U and the 
preference of down-regulated genes for codons ending in G and C. 
We can also infer the relationship between a pair of variables by the angle 
cosine formed by the two corresponding arrows. In this case, we can infer the 
relationship between two codons by the angle cosine formed by the arrows 
corresponding to the codons. From this perspective, almost all the codons ending 
in A and U formed angles close to 90° with codons ending in G and C in almost 
every example that we can take. Since the cosine of an angle of 90° is 0, we can 
infer that there is no relationship between codons ending in A and U and codons 
ending in G and C. From the same point of view, we can select some codons pairs 
ending In A and U that show higher relationship between both of them and the 
same is valid for codons ending in G and C. 
The covariance biplot corresponding to the deregulated gene of colorectal 
cancer datasets also revealed the existence of two groups one composed by up-
regulated genes (red-right side) and another group composed by down-regulated 
genes (green-left side). Nevertheless, the separation between those groups is not 
as clear as the results from the deregulated genes of all cancer datasets. This is 
observable from the frequency histogram (Figure 33). This can be explained by 
the higher number of genes that make the gene set when compared with the 
previous array. The colorectal gene sets have a higher number of genes because 
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the datasets correspond to only one type of cancer and the proximity of genes and 
their corresponding expression is higher than all the other cases. This also 
explains why there was a less clear tendency of codon usage pattern on the 
previous analysis. 
In what regards to the codons (variables) analysis, the direction preference 
remains the same as in the deregulated genes analysis biplot of all datasets. 
The covariance biplot corresponding to the deregulated genes of all cancer 
datasets where CTU2 was found deregulated revealed the existence of two 
groups, one composed by up-regulated genes (red-right side) and another group 
composed by down-regulated genes (green-left side). Furthermore, the codons 
(variables) ending in A and U nucleotides, which are represented by arrows, 
stretch in the direction of the up-regulated group of genes. Conversely, the codons 
ending in G and C nucleotides stretch in the direction of the up-regulated group of 
genes. 
The results of the gene set analysis of the datasets where CTU2 enzyme was 
found deregulated showed the formation of the same two groups of genes (up-
regulated and down-regulated genes) and the same tendencies of A/U and G/C 
codons of the other arrays of datasets. Since we only focused on the codons 
corresponding to the tRNAs modified by CTU2 tRNA modifying enzyme, these 
patterns are clearer on the plot. This leaves a place to assume a relationship 
between CTU2 and codon usage preferences on deregulated enriched GO gene 
sets. In this particular case it was important to assess the codon usage of genes in 
the gene sets where CTU2 was found deregulated because this enzyme catalyzes 
an important modification on the wobble position of specific tRNAs. The wobble 
modifications play critical roles in modulating codon recognition by restricting, 
expanding, or altering the decoding properties of the tRNAs (Ikeuchi et al., 2006). 
The CTU2 is up-regulated in all datasets analyzed. The up-regulation of CTU2 
may ultimately lead to an increase in modified tRNAs that, with their altered 
decoding properties, will set a preference for the last codon position (e.g. A/U 
instead of G/C). 
Aside from the described importance of this enzyme for the fidelity of 
translation, cancer-induced tRNAs typically correspond perfectly or via wobbling to 
 Chapter IV 
 
87 
 
codons enriched among the proliferation-processes genes (Gingold et al., 2014). If 
this is in fact the case, we can speculate based on our results that, since there is a 
preference for synonymous codon usage for these specific amino acids the tRNAs 
corresponding to the preferred codons are also altered. It is known that tRNA 
pools are altered in cancer (Waldman et al., 2009). This may be happening as a 
mechanism to enhance translation efficiency of specific genes enriched on these 
preferred codons. We may not yet conclude this because there is still controversy 
about the methods to study translation efficiency in humans.  Diverse studies have 
defined some measures of codon usage bias found in highly expressed genes 
(e.g. high CAI) as a links to translation efficiency (Lavner and Kotlar, 2005; dos 
Reis et al., 2004). However, recent studies suggest that this is plausible, yet 
indirect. Therefore, to study translation efficiency, a more suitable approach would 
be combining codon usage bias to tRNA pool co-adaptation and mRNA structure 
(Pop et al., 2014; Waldman et al., 2010). 
It is noteworthy that all the results from the covariance biplot of all the different 
arrays of datasets are concordant with the codon usage analysis described before. 
The usage of synonymous codons is not uniform and there is a strong 
preference toward certain codons in highly expressed genes when compared with 
other genes (Lavner and Kotlar, 2005). We cannot clearly conclude that tRNA 
modifications and tRNA modifying enzymes can alter the expression on human 
genes in cancer because we lack the additional data to draw this conclusion. 
Factors such as mRNA secondary structure, relative abundance of wobble base 
pairs, clustering of rare codons, interactions with modified tRNAs, ribosomal 
density, or presence of Shine-Dalgarno-like features in coding sequences  can 
further contribute to the regulation of gene expression through synonymous codon 
bias and tRNA dynamics (Kudla et al., 2009; Li et al., 2012; Novoa et al., 2012; 
Parmley and Huynen, 2009; Stadler and Fire, 2011; Tuller et al., 2010). 
However, our results point to a clear distinction on synonymous codon usage 
preferences when comparing groups of up-regulated and down-regulated genes 
(e.g. in covariance biplot of deregulated genes in cancer datasets (Figure 30) the 
codons CCU and CCC are synonymous codons that code proline. However, 
assuming the angle that the two vectors corresponding to these codons make, 
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there is no relationship in which regards codon usage of the two codons. 
Furthermore, there is a preference for CCU codon in up-regulated genes and there 
is a preference for CCC codon in down-regulated genes. In addition, the same 
behavior can be seen between another two synonymous codons GGU and GGC 
that code glycine. Interestingly, the codons CCU and GGU are closely related in 
which regards codon usage and this is also verified for CCC and GGC codons). 
Since synonymous changes for non-optimal codons can alter the expression of 
human genes (Kimchi-Sarfaty et al., 2007), we can assume a possible role of 
tRNA modifying enzymes on transcription regulation. 
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5. Final Remarks 
tRNA modifications are crucial for tRNA function, stability and codon:anticodon 
interactions. The levels of these modifications and its corresponding enzymes are 
altered in complex human diseases such as cancer, neurological disorders and 
mitochondrial-linked diseases. However, the molecular mechanisms behind these 
connections remain unknown. 
Overall, our data indicates a distinct codon usage and codon preference 
between up-regulated and down-regulated genes in cancer. This codon usage 
bias might be caused by the deregulation of specific tRNA modifying enzymes, as 
our analysis on CTU2 data indicates. Furthermore, our results suggest that the 
modification catalyzed by the CTU2 exerted a positive selection, causing a bias 
towards specific codons that are read by these modified tRNAs. However, it is 
difficult to draw clear conclusions between specific tRNA modifying enzymes and 
cancer because there are many enzymes deregulated at a given dataset. With the 
performed analyses other useful gene expression information was also extracted. 
The biological dichotomy of processes that we have noticed between up-regulated 
and down-regulated genes on our study, although known, is important in a gene 
expression analysis study. The distinct codon usage bias may augment the 
translation efficiency of some genes that otherwise, in a normal situation, would be 
translated less efficiently. In addition, this study suggests that codon usage bias in 
cancer shall be a strategy for regulating gene expression.  
Cancer is a multifactorial disease with a wide impact in human population and 
there is still a long way to go in what concerns the understanding of the genetic 
features of this disease as well as effective treatments. This study brings further 
support to the implication of tRNA modifying enzymes in cancer and the 
acquisition of the so called hallmarks of cancer as controlling agents of gene 
expression. 
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Table I – List of cancer microarray datasets used in this study and their GEO accession 
code (Part I). 
 
  
 
Dataset GEO accession
Dyrskjot Bladder 3 Superficial Bladder Cancer GSE3167
Dyrskjot Bladder Infiltrating Bladder Urothelial Carcinoma GSE89
Lee Brain Glioblastoma GSE4536
Sun Brain Anaplastic Astrocytoma GSE4290
Sun Brain Glioblastoma GSE4290
Sun Brain Oligodendroglioma GSE4290
Bredel Brain 2 Glioblastoma GSE2223
Biewenga Cervix Cervical Squamous Cell Carcinoma GSE7410
Pyeon Multi-cancer Cervical Cancer GSE6791
Pyeon Multi-cancer Cervical Squamous Cell Carcinoma GSE6791
Scotto Cervix 2 Cervical Squamous Cell Carcinoma GSE9750
Gaedcke Colorectal Rectal Adenocarcinoma GSE20842
Hong Colorectal Colorectal Carcinoma GSE9348
Kaiser Colon Cecum Adenocarcinoma GSE5206
Kaiser Colon Colon Adenocarcinoma GSE5206
Kaiser colon Colon Mucinous Adenocarcinoma GSE5206
Kaiser colon Rectal Adenocarcinoma GSE5206
Kaiser Colon Rectal Mucinous Adenocarcinoma GSE5206
Kaiser Colon Rectosigmoid Adenocarcinoma GSE5206
Sabates-Bellver Colon Colon Adenoma GSE8671
Sabates-Bellver Colon Rectal Adenoma GSE8671
Skrzypczak Colorectal 2 Colon Adenoma Epithelia GSE20916
Skrzypczak Colorectal 2 Colon Adenoma GSE20916
Skrzypczak Colorectal 2 Colon Carcinoma Epithelia GSE20916
Skrzypczak Colorectal 2 Colon Carcinoma GSE20916
Skrzypczak Colorectal Colorectal Adenocarcinoma GSE20916
Skrzypczak Colorectal Colorectal Carcinoma GSE20916
Hu Esophagus Esophageal Squamous Cell Carcinoma GSE20347
Su Esophagus 2 Esophageal Squamous Cell Carcinoma GSE23400
Cho Gastric Diffuse Gastric Adenocarcinoma GSE13861
Cho Gastric Gastric Intestinal Type Adenocarcinoma GSE13861
Cho Gastric Gastric Mixed Adenocarcinoma GSE13861
DErrico Gastric Diffuse Gastric Adenocarcinoma GSE13911
DErrico Gastric Gastric Intestinal Type Adenocarcinoma GSE13911
Estilo Head-Neck Tongue Squamous Cell Carcinoma GSE13601
Sengupta Head-Neck Nasopharyngeal Carcinoma GSE12452
Beroukhim Renal Non-Hereditary Clear Cell Renal Cell Carcinoma GSE14994
Jones Renal Chromophobe Renal Cell Carcinoma GSE15641
Jones Renal Clear Cell Renal Cell Carcinoma GSE15641
Jones Renal Papillary Renal Cell Carcinoma GSE15641
Jones Renal Renal Oncocytoma GSE15641
Jones Renal Renal Pelvis Urothelial Carcinoma GSE15641
Choi Leukemia Chronic Adult T-Cell Leukemia-Lymphoma GSE1466
Coustan-Smith Leukemia B-Cell Childhood Acute Lymphoblastic Leukemia GSE28497
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Table II – List of cancer microarray datasets used in this study and their GEO accession 
code (Part II). 
  
Dataset GEO accession
Coustan-Smith Leukemia T-Cell Childhood Acute Lymphoblastic Leukemia GSE28497
Mas Liver Hepatocellular Carcinoma GSE14323
Roessler Liver Hepatocellular Carcinoma GSE14520
Wurmbach Liver Hepatocellular Carcinoma GSE6764
Hou Lung Large Cell Lung Carcinoma GSE19188
Hou Lung Squamous Cell Lung Carcinoma GSE19188
Selamat Lung Lung Adenocarcinoma GSE32863
Su Lung Lung Adenocarcinoma GSE7670
Brune Lymphoma Diffuse Large B-Cell Lymphoma GSE12453
Compagno Lymphoma Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma GSE12195
Riker Melanoma Skin Basal Cell Carcinoma GSE7553
Riker Melanoma Skin Squamous Cell Carcinoma GSE7553
Agnelli Myeloma 3 Multiple Myeloma GSE13591
Agnelli Myeloma 3 Plasma Cell Leukemia GSE13591
Zhan Myeloma 3  Monoclonal Gammopathy of Undetermined Significance GSE5900
Zhan Myeloma 3 Smoldering Myeloma GSE5900
Pyeon Multi-cancer Floor of the Mouth Carcinoma GSE6791
Pyeon Multi-cancer Tongue Carcinoma GSE6791
Santegoets Vulva Vulvar Intraepithelial Neoplasia GSE5563
Bonome Ovarian Ovarian Carcinoma GSE26712
Barretina Sarcoma Dedifferentiated Liposarcoma GSE21122
Barretina Sarcoma Leiomyosarcoma GSE21122
Barretina Sarcoma Myxofibrosarcoma GSE21122
Barretina Sarcoma Myxoid-Round Cell Liposarcoma GSE21122
Barretina Sarcoma Pleomorphic Liposarcoma GSE21122
Detwiller Sarcoma Malignant Fibrous Histiocytoma GSE2719
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Table III – List of tRNA modifying enzymes used in this study. 
 
  
tRNA Modifying enzymes
ADAT3
IKBKAP
Elp2
Elp3
Elp4
Elp5
Elp6
KIAA1456
KTI12
TRIT1
URM1
CTU2
CTU1
PUS1
PUS3
TRMT1
TRMT2A
TRMT2B
NSUN2 
ALKBH8
TRMT10A
TRMT11
TYW1
TRMT12
LCMT2
TRMU
TRMT5
FTSJ1
TRMT61A
QTRT1
TRDMT1
TRMT112
TRMT1L
TRMT10C
PUSL1
PUS7L
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Table IV - List of cancer microarray datasets used in this study and the deregulation value 
(M-value) of tRNA modifying enzymes (Part I). 
 
  
Cancer Datasets ADAT3 ALKBH8 CTU1 CTU2 ELP2 ELP3 ELP4 ELP5 ELP6
Dyrskjot Bladder 3 Superficial Bladder Cancer
Dyrskjot Bladder Infiltrating Bladder Urothelial Carcinoma
Lee Brain Glioblastoma -0.58 -1.26 -0.63
Sun Brain Anaplastic Astrocytoma 0.78 0.54
Sun Brain Glioblastoma 0.54
Sun Brain Oligodendroglioma 1.07 0.55
Bredel Brain 2 Glioblastoma 
Biewenga Cervix Cervical Squamous Cell Carcinoma
Pyeon Multi-cancer Cervical Cancer -0.51 0.92 -0.59 0.69 0.65 1.10
Pyeon Multi-cancer Cervical Squamous Cell Carcinoma -0.51 0.92 -0.59 0.69 0.65 1.10
Scotto Cervix 2 Cervical Squamous Cell Carcinoma 1.06
Gaedcke Colorectal Rectal Adenocarcinoma 0.73 0.81
Hong Colorectal Colorectal Carcinoma 0.88 -0.70 -0.64 1.27
Kaiser Colon Cecum Adenocarcinoma 0.83
Kaiser Colon Colon Adenocarcinoma 0.78 -0.52
Kaiser Colon Colon Mucinous Adenocarcinoma 0.77 0.51
Kaiser Colon Rectal Adenocarcinoma 0.79 -0.81
Kaiser Colon Rectal Mucinous Adenocarcinoma -0.57 0.53 0.61 0.56 -0.82
Kaiser Colon Rectosigmoid Adenocarcinoma 0.89
Sabates-Bellver Colon Colon Adenoma 1.21 0.87 0.78
Sabates-Bellver Colon Rectal Adenoma 0.76 0.73 -0.58
Skrzypczak Colorectal 2 Colon Adenoma Epithelia 1.14 -1.00 0.79 0.99
Skrzypczak Colorectal 2 Colon Adenoma 0.90 1.10 0.56 0.58
Skrzypczak Colorectal 2 Colon Carcinoma Epithelia 0.99 -0.70 -0.89
Skrzypczak Colorectal 2 Colon Carcinoma 0.90 1.10 0.56 0.58
Skrzypczak Colorectal Colorectal Adenocarcinoma 0.72
Skrzypczak Colorectal Colorectal Carcinoma 0.77 0.54
Hu Esophagus Esophageal Squamous Cell Carcinoma
Su Esophagus 2 Esophageal Squamous Cell Carcinoma
Cho Gastric Diffuse Gastric Adenocarcinoma
Cho Gastric Gastric Intestinal Type Adenocarcinoma
Cho Gastric Gastric Mixed Adenocarcinoma
DErrico Gastric Diffuse Gastric Adenocarcinoma -1.14 -0.97
DErrico Gastric Gastric Intestinal Type Adenocarcinoma -0.74 -0.73 0.54 0.66
Estilo Head-Neck Tongue Squamous Cell Carcinoma
Sengupta Head-Neck Nasopharyngeal Carcinoma 0.54 0.51
Beroukhim Renal Non-Hereditary Clear Cell Renal Cell Carcinoma
Jones Renal Chromophobe Renal Cell Carcinoma 1.71
Jones Renal Clear Cell Renal Cell Carcinoma 0.55 0.66
Jones Renal Papillary Renal Cell Carcinoma 1.47
Jones Renal Renal Oncocytoma 0.68 1.81
Jones Renal Renal Pelvis Urothelial Carcinoma 1.33
Choi Leukemia Chronic Adult T-Cell Leukemia-Lymphoma -0.81
Coustan-Smith Leukemia B-Cell Childhood Acute Lymphoblastic Leukemia
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Table V - List of cancer microarray datasets used in this study and the deregulation value 
(M-value) of tRNA modifying enzymes (Part II). 
 
Cancer Datasets ADAT3 ALKBH8 CTU1 CTU2 ELP2 ELP3 ELP4 ELP5 ELP6
Coustan-Smith Leukemia T-Cell Childhood Acute Lymphoblastic Leukemia
Mas Liver Hepatocellular Carcinoma
Roessler Liver Hepatocellular Carcinoma
Wurmbach Liver Hepatocellular Carcinoma -0.81
Hou Lung Large Cell Lung Carcinoma 0.56
Hou Lung Squamous Cell Lung Carcinoma -1.17 -0.68
Selamat Lung Lung Adenocarcinoma
Su Lung Lung Adenocarcinoma
Brune Lymphoma Diffuse Large B-Cell Lymphoma 0.60 0.69 0.69 0.57
Compagno Lymphoma Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma -2.26 -2.83
Riker Melanoma Skin Basal Cell Carcinoma -0.67 0.77 -0.86 0.77 1.45
Riker Melanoma Skin Squamous Cell Carcinoma -0.90 -0.82 1.62
Agnelli Myeloma 3 Multiple Myeloma
Agnelli Myeloma 3 Plasma Cell Leukemia
Zhan Myeloma 3  Monoclonal Gammopathy of Undetermined Significance 0.99 1.59
Zhan Myeloma 3 Smoldering Myeloma 1.60 1.31 0.73 0.60
Pyeon Multi-cancer Floor of the Mouth Carcinoma 0.54 0.66 0.68 0.71
Pyeon Multi-cancer Tongue Carcinoma 0.82
Santegoets Vulva Vulvar Intraepithelial Neoplasia
Bonome Ovarian Ovarian Carcinoma -0.67 0.82
Barretina Sarcoma Dedifferentiated Liposarcoma
Barretina Sarcoma Leiomyosarcoma
Barretina Sarcoma Myxofibrosarcoma
Barretina Sarcoma Myxoid-Round Cell Liposarcoma
Barretina Sarcoma Pleomorphic Liposarcoma
Detwiller Sarcoma Malignant Fibrous Histiocytoma
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Table VI - List of cancer microarray datasets used in this study and the deregulation value 
(M-value) of tRNA modifying enzymes (Part III). 
 
  
Cancer Datasets FTSJ1 IKBKAP KIAA1456 KTI12 LCMT2 NSUN2 PUS1 PUS3 PUS7L
Dyrskjot Bladder 3 Superficial Bladder Cancer 0.62 0.95
Dyrskjot Bladder Infiltrating Bladder Urothelial Carcinoma 0.69 0.60 0.79
Lee Brain Glioblastoma 1.95 2.38
Sun Brain Anaplastic Astrocytoma 0.76
Sun Brain Glioblastoma -0.88
Sun Brain Oligodendroglioma 0.71 1.02
Bredel Brain 2 Glioblastoma -1.15
Biewenga Cervix Cervical Squamous Cell Carcinoma -0.73 -1.48 0.77
Pyeon Multi-cancer Cervical Cancer 0.93 1.39 0.60 0.56 0.77
Pyeon Multi-cancer Cervical Squamous Cell Carcinoma 0.93 1.39 0.60 0.56 0.77
Scotto Cervix 2 Cervical Squamous Cell Carcinoma -0.71 0.63 -0.62
Gaedcke Colorectal Rectal Adenocarcinoma 1.05 -0.66 0.86
Hong Colorectal Colorectal Carcinoma 1.15 0.75 1.19 0.52 0.65
Kaiser Colon Cecum Adenocarcinoma 0.69 0.64 0.86
Kaiser Colon Colon Adenocarcinoma -0.55 0.77 0.74
Kaiser Colon Colon Mucinous Adenocarcinoma 0.65 -0.76 0.69 0.63
Kaiser Colon Rectal Adenocarcinoma -0.52 0.60
Kaiser Colon Rectal Mucinous Adenocarcinoma -0.76 0.67
Kaiser Colon Rectosigmoid Adenocarcinoma 0.62 -0.64 0.75 0.75
Sabates-Bellver Colon Colon Adenoma 0.77 0.67 0.56 0.96 0.66
Sabates-Bellver Colon Rectal Adenoma 0.78 0.65 0.87 0.53
Skrzypczak Colorectal 2 Colon Adenoma Epithelia 0.83 0.64 -1.95 0.64 1.52 1.32
Skrzypczak Colorectal 2 Colon Adenoma 1.65 0.81 -1.21 1.59 2.15
Skrzypczak Colorectal 2 Colon Carcinoma Epithelia 1.02 0.98 -2.11 1.57 -0.62 0.62
Skrzypczak Colorectal 2 Colon Carcinoma 1.65 0.81 -1.21 1.59 2.15
Skrzypczak Colorectal Colorectal Adenocarcinoma 0.80 0.81 0.52 1.29 0.60 0.84
Skrzypczak Colorectal Colorectal Carcinoma 1.26 1.61 0.51 1.11
Hu Esophagus Esophageal Squamous Cell Carcinoma 0.76
Su Esophagus 2 Esophageal Squamous Cell Carcinoma 0.67 0.58
Cho Gastric Diffuse Gastric Adenocarcinoma 0.67
Cho Gastric Gastric Intestinal Type Adenocarcinoma 0.71
Cho Gastric Gastric Mixed Adenocarcinoma 0.79
DErrico Gastric Diffuse Gastric Adenocarcinoma 0.58 0.86
DErrico Gastric Gastric Intestinal Type Adenocarcinoma 0.92
Estilo Head-Neck Tongue Squamous Cell Carcinoma 0.51
Sengupta Head-Neck Nasopharyngeal Carcinoma 0.71
Beroukhim Renal Non-Hereditary Clear Cell Renal Cell Carcinoma
Jones Renal Chromophobe Renal Cell Carcinoma
Jones Renal Clear Cell Renal Cell Carcinoma 0.82 0.63 0.79 0.50
Jones Renal Papillary Renal Cell Carcinoma 1.74 -0.75
Jones Renal Renal Oncocytoma -0.78
Jones Renal Renal Pelvis Urothelial Carcinoma 1.59 0.58 -0.55
Choi Leukemia Chronic Adult T-Cell Leukemia-Lymphoma -0.90 -0.82
Coustan-Smith Leukemia B-Cell Childhood Acute Lymphoblastic Leukemia 0.63
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Table VII - List of cancer microarray datasets used in this study and the deregulation value 
(M-value) of tRNA modifying enzymes (Part IV). 
 
Cancer Datasets FTSJ1 IKBKAP KIAA1456 KTI12 LCMT2 NSUN2 PUS1 PUS3 PUS7L
Coustan-Smith Leukemia T-Cell Childhood Acute Lymphoblastic Leukemia 0.65 0.81 0.73
Mas Liver Hepatocellular Carcinoma -0.80 -0.69 -0.70 -0.76
Roessler Liver Hepatocellular Carcinoma 0.57 0.75 0.93
Wurmbach Liver Hepatocellular Carcinoma 0.65 -0.72 0.99
Hou Lung Large Cell Lung Carcinoma 0.75 0.83
Hou Lung Squamous Cell Lung Carcinoma -0.60 0.82 0.76
Selamat Lung Lung Adenocarcinoma 0.66
Su Lung Lung Adenocarcinoma 0.52 -0.56 0.83
Brune Lymphoma Diffuse Large B-Cell Lymphoma -0.52 0.52 0.91
Compagno Lymphoma Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma -2.68 -1.76
Riker Melanoma Skin Basal Cell Carcinoma 0.56 1.43 0.53 1.05
Riker Melanoma Skin Squamous Cell Carcinoma 0.61 -1.87 0.57 0.54
Agnelli Myeloma 3 Multiple Myeloma 0.72
Agnelli Myeloma 3 Plasma Cell Leukemia 0.51 0.92 0.76
Zhan Myeloma 3  Monoclonal Gammopathy of Undetermined Significance -0.64 -0.54 0.76
Zhan Myeloma 3 Smoldering Myeloma 0.62 -1.03 0.72 0.87 0.58
Pyeon Multi-cancer Floor of the Mouth Carcinoma 0.55 1.27 -0.55 0.73 1.07
Pyeon Multi-cancer Tongue Carcinoma 0.65 0.59 -0.54 0.88
Santegoets Vulva Vulvar Intraepithelial Neoplasia 0.58 1.00 0.86 0.53
Bonome Ovarian Ovarian Carcinoma 0.51 -1.49 -0.68
Barretina Sarcoma Dedifferentiated Liposarcoma 0.73
Barretina Sarcoma Leiomyosarcoma 0.51 0.91
Barretina Sarcoma Myxofibrosarcoma 1.45 1.38
Barretina Sarcoma Myxoid-Round Cell Liposarcoma 1.11
Barretina Sarcoma Pleomorphic Liposarcoma 0.73 1.09
Detwiller Sarcoma Malignant Fibrous Histiocytoma 0.95
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Table VIII - List of cancer microarray datasets used in this study and the deregulation value 
(M-value) of tRNA modifying enzymes (Part V). 
 
 
 
  
Cancer Datasets PUSL1 QTRT1 TRDMT1 TRIT1 TRMT1 TRMT10A TRMT10C TRMT11 TRMT112
Dyrskjot Bladder 3 Superficial Bladder Cancer 0.82 0.78 0.77
Dyrskjot Bladder Infiltrating Bladder Urothelial Carcinoma 0.82 1.08
Lee Brain Glioblastoma 1.02 -0.73
Sun Brain Anaplastic Astrocytoma 0.77
Sun Brain Glioblastoma 
Sun Brain Oligodendroglioma 
Bredel Brain 2 Glioblastoma -0.54
Biewenga Cervix Cervical Squamous Cell Carcinoma -1.09
Pyeon Multi-cancer Cervical Cancer 0.83 0.60 0.65 1.79 1.87
Pyeon Multi-cancer Cervical Squamous Cell Carcinoma 0.83 0.60 0.65 1.79 1.87
Scotto Cervix 2 Cervical Squamous Cell Carcinoma 1.16 -1.20 -0.83
Gaedcke Colorectal Rectal Adenocarcinoma 0.58 0.74 1.07
Hong Colorectal Colorectal Carcinoma 0.67 0.67 0.52 1.95 -0.75 0.92
Kaiser Colon Cecum Adenocarcinoma 0.53 0.58 0.73
Kaiser Colon Colon Adenocarcinoma 0.60 0.55 0.94
Kaiser Colon Colon Mucinous Adenocarcinoma 0.54 0.90
Kaiser Colon Rectal Adenocarcinoma -0.60 0.75
Kaiser Colon Rectal Mucinous Adenocarcinoma 0.66 0.67 0.81
Kaiser Colon Rectosigmoid Adenocarcinoma 0.51 -0.53 0.80
Sabates-Bellver Colon Colon Adenoma 1.11 0.80 1.63 0.71 0.76 0.81
Sabates-Bellver Colon Rectal Adenoma 0.58 0.74 0.57 1.31 0.63 0.74
Skrzypczak Colorectal 2 Colon Adenoma Epithelia 1.03 0.84 1.26 1.90 -0.88 0.76 0.80 1.15
Skrzypczak Colorectal 2 Colon Adenoma 1.82 0.95 2.73 -0.53 1.15 1.17 1.64
Skrzypczak Colorectal 2 Colon Carcinoma Epithelia 0.82 0.56 1.56 1.03 1.29 1.31
Skrzypczak Colorectal 2 Colon Carcinoma 1.82 0.95 2.73 -0.53 1.15 1.17 1.64
Skrzypczak Colorectal Colorectal Adenocarcinoma 0.61 1.01 0.93 0.90 0.75 0.69 0.76
Skrzypczak Colorectal Colorectal Carcinoma 0.93 0.73 1.02 0.95 0.98 1.19
Hu Esophagus Esophageal Squamous Cell Carcinoma 0.53 0.54
Su Esophagus 2 Esophageal Squamous Cell Carcinoma 0.50 0.60
Cho Gastric Diffuse Gastric Adenocarcinoma 0.53
Cho Gastric Gastric Intestinal Type Adenocarcinoma
Cho Gastric Gastric Mixed Adenocarcinoma 0.60
DErrico Gastric Diffuse Gastric Adenocarcinoma 0.65 1.20 0.68
DErrico Gastric Gastric Intestinal Type Adenocarcinoma 0.52 -0.75 1.21 0.55
Estilo Head-Neck Tongue Squamous Cell Carcinoma -0.74 0.56
Sengupta Head-Neck Nasopharyngeal Carcinoma 0.52 0.60
Beroukhim Renal Non-Hereditary Clear Cell Renal Cell Carcinoma 0.68
Jones Renal Chromophobe Renal Cell Carcinoma -0.57
Jones Renal Clear Cell Renal Cell Carcinoma 0.60 0.68 1.00 0.52 1.21
Jones Renal Papillary Renal Cell Carcinoma 0.64
Jones Renal Renal Oncocytoma 0.50 0.61
Jones Renal Renal Pelvis Urothelial Carcinoma 0.69 0.86
Choi Leukemia Chronic Adult T-Cell Leukemia-Lymphoma -0.96
Coustan-Smith Leukemia B-Cell Childhood Acute Lymphoblastic Leukemia 1.01
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Table IX - List of cancer microarray datasets used in this study and the deregulation value 
(M-value) of tRNA modifying enzymes (Part VI). 
 
  
Cancer Datasets PUSL1 QTRT1 TRDMT1 TRIT1 TRMT1 TRMT10A TRMT10C TRMT11 TRMT112
Coustan-Smith Leukemia T-Cell Childhood Acute Lymphoblastic Leukemia 1.20 0.72
Mas Liver Hepatocellular Carcinoma -0.82 -0.90
Roessler Liver Hepatocellular Carcinoma 0.84 0.62
Wurmbach Liver Hepatocellular Carcinoma 0.66 -0.68
Hou Lung Large Cell Lung Carcinoma 0.81 0.85 0.65
Hou Lung Squamous Cell Lung Carcinoma -0.72 0.66 -0.57 0.54
Selamat Lung Lung Adenocarcinoma 0.69
Su Lung Lung Adenocarcinoma 1.27 0.57
Brune Lymphoma Diffuse Large B-Cell Lymphoma 0.54 0.78 0.54 1.13
Compagno Lymphoma Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma -1.98
Riker Melanoma Skin Basal Cell Carcinoma -1.12 0.52
Riker Melanoma Skin Squamous Cell Carcinoma 0.52
Agnelli Myeloma 3 Multiple Myeloma 0.60 0.56
Agnelli Myeloma 3 Plasma Cell Leukemia 0.81 0.70 0.72
Zhan Myeloma 3  Monoclonal Gammopathy of Undetermined Significance 0.85 0.53
Zhan Myeloma 3 Smoldering Myeloma 0.60 1.09 0.60 0.86 0.65
Pyeon Multi-cancer Floor of the Mouth Carcinoma 0.57 1.10 0.94 0.57 0.93
Pyeon Multi-cancer Tongue Carcinoma 0.62 0.57 0.84
Santegoets Vulva Vulvar Intraepithelial Neoplasia 1.04 0.55
Bonome Ovarian Ovarian Carcinoma 0.84 0.63 -0.66
Barretina Sarcoma Dedifferentiated Liposarcoma 0.60
Barretina Sarcoma Leiomyosarcoma 0.71 0.86
Barretina Sarcoma Myxofibrosarcoma 0.94
Barretina Sarcoma Myxoid-Round Cell Liposarcoma 0.64 1.10 0.71
Barretina Sarcoma Pleomorphic Liposarcoma 0.91 0.61
Detwiller Sarcoma Malignant Fibrous Histiocytoma 1.15 1.59
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Table X - List of cancer microarray datasets used in this study and the deregulation value 
(M-value) of tRNA modifying enzymes (Part VII). 
 
Cancer Datasets TRMT12 TRMT1L TRMT2A TRMT2B TRMT5 TRMT61A TRMU TYW1 URM1
Dyrskjot Bladder 3 Superficial Bladder Cancer 0.78 0.57
Dyrskjot Bladder Infiltrating Bladder Urothelial Carcinoma 0.86
Lee Brain Glioblastoma -0.93 -0.62
Sun Brain Anaplastic Astrocytoma 1.04 0.76
Sun Brain Glioblastoma 
Sun Brain Oligodendroglioma 0.92
Bredel Brain 2 Glioblastoma -0.91 -1.79
Biewenga Cervix Cervical Squamous Cell Carcinoma 0.59
Pyeon Multi-cancer Cervical Cancer 0.94 0.99 1.38
Pyeon Multi-cancer Cervical Squamous Cell Carcinoma 0.94 0.99 1.38
Scotto Cervix 2 Cervical Squamous Cell Carcinoma -0.58
Gaedcke Colorectal Rectal Adenocarcinoma 0.65 0.62
Hong Colorectal Colorectal Carcinoma 0.50 0.97 0.61 0.60
Kaiser Colon Cecum Adenocarcinoma 0.59 0.58
Kaiser Colon Colon Adenocarcinoma 0.81
Kaiser Colon Colon Mucinous Adenocarcinoma 0.63 0.70
Kaiser Colon Rectal Adenocarcinoma -0.53
Kaiser Colon Rectal Mucinous Adenocarcinoma 0.75 0.79
Kaiser Colon Rectosigmoid Adenocarcinoma 0.82
Sabates-Bellver Colon Colon Adenoma 0.79 1.40 0.65 0.58
Sabates-Bellver Colon Rectal Adenoma 0.56 0.54 0.72 0.54 0.68
Skrzypczak Colorectal 2 Colon Adenoma Epithelia 1.66 0.52 0.50
Skrzypczak Colorectal 2 Colon Adenoma 0.54 0.82 0.76
Skrzypczak Colorectal 2 Colon Carcinoma Epithelia 0.50 -0.78 0.53
Skrzypczak Colorectal 2 Colon Carcinoma 0.54 0.82 0.76
Skrzypczak Colorectal Colorectal Adenocarcinoma 1.21
Skrzypczak Colorectal Colorectal Carcinoma 1.04
Hu Esophagus Esophageal Squamous Cell Carcinoma 0.88
Su Esophagus 2 Esophageal Squamous Cell Carcinoma
Cho Gastric Diffuse Gastric Adenocarcinoma
Cho Gastric Gastric Intestinal Type Adenocarcinoma 0.63
Cho Gastric Gastric Mixed Adenocarcinoma 0.73
DErrico Gastric Diffuse Gastric Adenocarcinoma
DErrico Gastric Gastric Intestinal Type Adenocarcinoma 0.61 0.54
Estilo Head-Neck Tongue Squamous Cell Carcinoma 0.58
Sengupta Head-Neck Nasopharyngeal Carcinoma -0.58
Beroukhim Renal Non-Hereditary Clear Cell Renal Cell Carcinoma
Jones Renal Chromophobe Renal Cell Carcinoma -0.51 0.99
Jones Renal Clear Cell Renal Cell Carcinoma 0.52 0.79 0.72 0.87 2.90 0.82
Jones Renal Papillary Renal Cell Carcinoma 2.48
Jones Renal Renal Oncocytoma
Jones Renal Renal Pelvis Urothelial Carcinoma 2.33
Choi Leukemia Chronic Adult T-Cell Leukemia-Lymphoma -0.57 -1.42
Coustan-Smith Leukemia B-Cell Childhood Acute Lymphoblastic Leukemia 0.51 1.99 -1.04
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Table XI - List of cancer microarray datasets used in this study and the deregulation value 
(M-value) of tRNA modifying enzymes (Part VIII). 
 
Cancer Datasets TRMT12 TRMT1L TRMT2A TRMT2B TRMT5 TRMT61A TRMU TYW1 URM1
Coustan-Smith Leukemia T-Cell Childhood Acute Lymphoblastic Leukemia 1.65 -0.71
Mas Liver Hepatocellular Carcinoma -0.60 0.67
Roessler Liver Hepatocellular Carcinoma
Wurmbach Liver Hepatocellular Carcinoma 0.83 0.60
Hou Lung Large Cell Lung Carcinoma 0.53 0.61 0.72 0.52
Hou Lung Squamous Cell Lung Carcinoma 0.92
Selamat Lung Lung Adenocarcinoma
Su Lung Lung Adenocarcinoma 0.85 0.72
Brune Lymphoma Diffuse Large B-Cell Lymphoma 0.79
Compagno Lymphoma Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
Riker Melanoma Skin Basal Cell Carcinoma 0.71 0.56 0.51
Riker Melanoma Skin Squamous Cell Carcinoma -0.75 1.49
Agnelli Myeloma 3 Multiple Myeloma
Agnelli Myeloma 3 Plasma Cell Leukemia 0.54
Zhan Myeloma 3  Monoclonal Gammopathy of Undetermined Significance 0.89 0.53
Zhan Myeloma 3 Smoldering Myeloma 1.31 0.91 0.61 0.51
Pyeon Multi-cancer Floor of the Mouth Carcinoma 1.04 1.10 0.52
Pyeon Multi-cancer Tongue Carcinoma 0.74
Santegoets Vulva Vulvar Intraepithelial Neoplasia 0.60 0.88 0.75
Bonome Ovarian Ovarian Carcinoma 0.58 -1.73 0.57 -0.70
Barretina Sarcoma Dedifferentiated Liposarcoma 0.72
Barretina Sarcoma Leiomyosarcoma 0.80
Barretina Sarcoma Myxofibrosarcoma 0.80 0.96
Barretina Sarcoma Myxoid-Round Cell Liposarcoma 0.99
Barretina Sarcoma Pleomorphic Liposarcoma 1.03
Detwiller Sarcoma Malignant Fibrous Histiocytoma 0.50
